
    
<!DOCTYPE html>




<html lang="en" >
<head >
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">

    <!-- Mobile properties -->
    <meta name="HandheldFriendly" content="True">
    <meta name="MobileOptimized" content="320">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

  
    <!-- Stylesheets -->
    <link rel="stylesheet" href="/pmc/static/CACHE/css/output.cc84172e9e16.css" type="text/css">
  
  <link rel="stylesheet" href="/pmc/static/CACHE/css/output.b634933a977d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.913c7dcab8ff.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.3766d7ad0d2d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.e3c3c2c84eb3.css" type="text/css">

  
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css"/>
  
<link type="text/css" href="/pmc/static/bundles/base/base.a2ef7ca69e4b20dff539.css" rel="stylesheet" />


    <link rel="stylesheet" href="/corehtml/pmc/css/fonts/stix/stixfonts.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.18/pmcrefs1.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/pmc2020_1.1/ncbi_web.min.css?_=a" type="text/css" /><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-journal.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style>

    <link type="text/css" href="/pmc/static/bundles/article/article.3c5d12ff2e4beea20136.css" rel="stylesheet" />
    <link type="text/css" href="/pmc/static/django_pmc_cite_box/lib/cite-box.css" rel="stylesheet" />


    <title>Metabolomic signatures of carfilzomib&#8208;related cardiotoxicity in patients with multiple myeloma - PMC</title>

  
  <!-- Favicons -->
  <link rel="shortcut icon" type="image/ico" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico" />
  <link rel="icon" type="image/png" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.png" />

  <!-- 192x192, as recommended for Android
  http://updates.html5rocks.com/2014/11/Support-for-theme-color-in-Chrome-39-for-Android
  -->
  <link rel="icon" type="image/png" sizes="192x192" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-192.png" />

  <!-- 57x57 (precomposed) for iPhone 3GS, pre-2011 iPod Touch and older Android devices -->
  <link rel="apple-touch-icon-precomposed" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-57.png">
  <!-- 72x72 (precomposed) for 1st generation iPad, iPad 2 and iPad mini -->
  <link rel="apple-touch-icon-precomposed" sizes="72x72" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-72.png">
  <!-- 114x114 (precomposed) for iPhone 4, 4S, 5 and post-2011 iPod Touch -->
  <link rel="apple-touch-icon-precomposed" sizes="114x114" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-114.png">
  <!-- 144x144 (precomposed) for iPad 3rd and 4th generation -->
  <link rel="apple-touch-icon-precomposed" sizes="144x144" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-144.png">



    
        <!-- Logging params: Pinger defaults -->

<meta name="ncbi_app" content="pmc-frontend" />

<meta name="ncbi_db" content="pmc" />

<meta name="ncbi_phid" content="322C300B24F392050000488D3D4B6C84.1.m_2" />


        <!-- Logging params: Pinger custom -->

<meta name="ncbi_pdid" content="article" />

<meta name="ncbi_op" content="retrieved" />

<meta name="ncbi_app_version" content="0.0" />

<meta name="ncbi_domain" content="cts" />

<meta name="ncbi_type" content="fulltext" />

<meta name="ncbi_pcid" content="/articles/PMC11116757/" />


    


    <script>
        
            var ncbiBaseUrl = "https://www.ncbi.nlm.nih.gov";
        
        var useOfficialGovtHeader = true;
    </script>


    <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11116757/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="Clinical and Translational Science" /><meta name="citation_title" content="Metabolomic signatures of carfilzomib&#x02010;related cardiotoxicity in patients with multiple myeloma" /><meta name="citation_author" content="Samia Shabnaz" /><meta name="citation_author_institution" content="Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville Florida, USA" /><meta name="citation_author" content="Trang N. Nguyen" /><meta name="citation_author_institution" content="Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville Florida, USA" /><meta name="citation_author" content="Roy Williams" /><meta name="citation_author_institution" content="Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville Florida, USA" /><meta name="citation_author" content="Samuel M. Rubinstein" /><meta name="citation_author_institution" content="Department of Medicine, Division of Hematology, University of North Carolina, Chapel Hill North Carolina, USA" /><meta name="citation_author" content="Timothy J. Garrett" /><meta name="citation_author_institution" content="Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville Florida, USA" /><meta name="citation_author" content="Marwa Tantawy" /><meta name="citation_author_institution" content="Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville Florida, USA" /><meta name="citation_author" content="Michael G. Fradley" /><meta name="citation_author_institution" content="Cardio&#x02010;Oncology Center of Excellence, Division of Cardiology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia Pennsylvania, USA" /><meta name="citation_author" content="Mohammed E. Alomar" /><meta name="citation_author_institution" content="Department of Malignant Hematology, H. Lee Moffitt Cancer Center &#x00026; Research Institute, Tampa Florida, USA" /><meta name="citation_author" content="Kenneth H. Shain" /><meta name="citation_author_institution" content="Department of Malignant Hematology, H. Lee Moffitt Cancer Center &#x00026; Research Institute, Tampa Florida, USA" /><meta name="citation_author" content="Rachid C. Baz" /><meta name="citation_author_institution" content="Department of Malignant Hematology, H. Lee Moffitt Cancer Center &#x00026; Research Institute, Tampa Florida, USA" /><meta name="citation_author" content="Daniel Lenihan" /><meta name="citation_author_institution" content="Cape Cardiology Group, Saint Francis Medical Center, Cape Girardeau Missouri, USA" /><meta name="citation_author" content="Robert F. Cornell" /><meta name="citation_author_institution" content="Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville Tennessee, USA" /><meta name="citation_author" content="Qing Lu" /><meta name="citation_author_institution" content="Department of Biostatistics, College of Public Health and Health Professions &#x00026; College of Medicine, University of Florida, Gainesville Florida, USA" /><meta name="citation_author" content="Yan Gong" /><meta name="citation_author_institution" content="Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville Florida, USA" /><meta name="citation_author_institution" content="Cardio&#x02010;Oncology Working Group, UF Health Cancer Center, Gainesville Florida, USA" /><meta name="citation_publication_date" content="2024/05" /><meta name="citation_issue" content="5" /><meta name="citation_volume" content="17" /><meta name="citation_doi" content="10.1111/cts.13828" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC11116757/?report=abstract" /><meta name="citation_fulltext_html_url" content="/pmc/articles/PMC11116757/" /><meta name="citation_pmid" content="38783568" /><meta name="DC.Title" content="Metabolomic signatures of carfilzomib&#x02010;related cardiotoxicity in patients with multiple myeloma" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="Wiley" /><meta name="DC.Contributor" content="Samia Shabnaz" /><meta name="DC.Contributor" content="Trang N. Nguyen" /><meta name="DC.Contributor" content="Roy Williams" /><meta name="DC.Contributor" content="Samuel M. Rubinstein" /><meta name="DC.Contributor" content="Timothy J. Garrett" /><meta name="DC.Contributor" content="Marwa Tantawy" /><meta name="DC.Contributor" content="Michael G. Fradley" /><meta name="DC.Contributor" content="Mohammed E. Alomar" /><meta name="DC.Contributor" content="Kenneth H. Shain" /><meta name="DC.Contributor" content="Rachid C. Baz" /><meta name="DC.Contributor" content="Daniel Lenihan" /><meta name="DC.Contributor" content="Robert F. Cornell" /><meta name="DC.Contributor" content="Qing Lu" /><meta name="DC.Contributor" content="Yan Gong" /><meta name="DC.Date" content="2024 May" /><meta name="DC.Identifier" content="10.1111/cts.13828" /><meta name="DC.Language" content="en" /><meta property="og:title" content="Metabolomic signatures of carfilzomib&#x02010;related cardiotoxicity in patients with multiple myeloma" /><meta property="og:type" content="article" /><meta property="og:description" content="As a treatment for relapsed or refractory multiple myeloma (MM), carfilzomib has been associated with a significant risk of cardiovascular adverse events (CVAE). The goals of our study were to evaluate the metabolomic profile of MM patients to identify ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11116757/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0" /><meta name="twitter:card" content="summary_large_image" /><meta name="twitter:site" content="@ncbi" /><meta name="ncbi_feature" content="associated_data" />


</head>
<body >

   
    
        <button
          class="back-to-top back-to-top--bottom"
          data-ga-category="pagination"
          data-ga-action="back_to_top">
          Back to Top
        </button>
    

    <a class="usa-skipnav" href="#main-content">Skip to main content</a>
    <!-- ========== BEGIN HEADER ========== -->
<section class="usa-banner" style="display: none;">
  <div class="usa-accordion">
    <header class="usa-banner-header">
      <div class="usa-grid usa-banner-inner">
        <img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
        <p>An official website of the United States government</p>
        <button
          class="usa-accordion-button usa-banner-button"
          aria-expanded="false"
          aria-controls="gov-banner-top"
        >
          <span class="usa-banner-button-text">Here's how you know</span>
        </button>
      </div>
    </header>
    <div
      class="usa-banner-content usa-grid usa-accordion-content"
      id="gov-banner-top"
    >
      <div class="usa-banner-guidance-gov usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg"
          alt="Dot gov"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The .gov means it’s official.</strong>
            <br />
            Federal government websites often end in .gov or .mil. Before
            sharing sensitive information, make sure you’re on a federal
            government site.
          </p>
        </div>
      </div>
      <div class="usa-banner-guidance-ssl usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg"
          alt="Https"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The site is secure.</strong>
            <br />
            The <strong>https://</strong> ensures that you are connecting to the
            official website and that any information you provide is encrypted
            and transmitted securely.
          </p>
        </div>
      </div>
    </div>
  </div>
</section>
<div class="usa-overlay"></div>
<header class="ncbi-header" role="banner" data-section="Header">

	<div class="usa-grid">
		<div class="usa-width-one-whole">

            <div class="ncbi-header__logo">
                <a href="https://www.ncbi.nlm.nih.gov/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
                  <img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
                </a>
            </div>

			<div class="ncbi-header__account">
				<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
				<button id="account_info" class="header-button" style="display:none"
						aria-controls="account_popup">
					<span class="fa fa-user" aria-hidden="true"></span>
					<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
					<span class="sr-only">Show account info</span>
				</button>
			</div>

			<div class="ncbi-popup-anchor">
				<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
					<div class="ncbi-popup-head">
						<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu"><span class="fa fa-times"></span><span class="usa-sr-only">Close</span></button>
						<h4>Account</h4>
					</div>
					<div class="account-user-info">
						Logged in as:<br/>
						<b><span class="username" id="uname_long">username</span></b>
					</div>
					<div class="account-links">
						<ul class="usa-unstyled-list">
							<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
							<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
							<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
							<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
						</ul>
					</div>
				</div>
			</div>

		</div>
	</div>
</header>
<div role="navigation" aria-label="access keys">
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
</div>
<section data-section="Alerts">
	<div class="ncbi-alerts-placeholder"></div>
</section>
<!-- ========== END HEADER ========== -->

    
    


    
        

<section class="pmc-alerts">
    
    <div role="alert" class="pmc-alert pmc-alert--info" role="region" aria-label="Alert" aria-hidden="false"  data-key="pmc-alert-welcome">
        <div class="pmc-alert__body pmc-alert--ncbi-icon">
            <div class="pmc-alert__content">
                <p>
                    <strong>
                        Preview improvements coming to the PMC website in October 2024.
                        <a href="https://ncbiinsights.ncbi.nlm.nih.gov/2024/03/14/preview-pmc-improvements/" data-ga-category="cloud_beta_banner" data-ga-label="learn_more" data-ga-action="on_pmc2020">Learn More</a> or
                        <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11116757/" data-ga-category="cloud_beta_banner" data-ga-action="on_pmc2020" data-ga-label="go_to_cloud">Try it out now</a>.
                    </strong>
                </p>
            </div>
        </div>
    </div>
    
</section>
    

    
    
        
        <header class="pmc-header usa-header-extended" role="banner">
    <div class="pmc-header__bar">
        <div class="pmc-header__control usa-accordion">
            
                <button class="usa-menu-btn pmc-header--button pmc-header--left">
                    <i class="fa fa-ellipsis-v" aria-hidden="true"></i>
                </button>
            

            <div class="usa-logo pmc-header__logo pmc-header--stretch
                
               " id="extended-mega-logo">
                <div class="usa-logo-text">
                    <a href="/pmc/" title="Home" aria-label="Home" ></a>
                </div>
            </div>
            <button class="usa-accordion-button pmc-header--right pmc-header--button pmc-header__search--control pmc-header--right" aria-expanded="false" aria-controls="a1">
                <i class="fa fa-search" aria-hidden="true"></i>
                <i class="fa fa-times" aria-hidden="true"></i>
            </button>
        </div>
        <div class="pmc-header__search usa-accordion-content" id="a1">
            <div role="search"  class="pmc-header--stretch"  >
    <form class="usa-search " autocomplete="off">
        <div>
              <label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
              <span class="clearable">
                <input
                  required="required"
                  autocomplete-url="/pmc/autocomplete/pmc/"
                  placeholder="Search PMC Full-Text Archive"
                  id="pmc-search" type="search" name="term"/>
                  <i class="clear-btn" ></i>
              </span>
              <button type="submit" formaction="/pmc/">
                <span class="usa-search-submit-text">Search in PMC</span>
              </button>
        </div>
    </form>
</div>


            <ul class="usa-unstyled-list usa-nav-secondary-links pmc-header--offset-two">
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/advanced" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        <a  href="/pmc/about/userguide/" data-ga-action="featured_link"
                        data-ga-label="user guide">
                            User Guide
                        </a>
                    </li>
            </ul>
        </div>
    </div>
     <nav role="navigation" class="usa-nav ">
        <button class="usa-nav-close">
            <i class="fa fa-times" aria-hidden="true"></i>
        </button>
        <div class="usa-breadcrumb usa-breadcrumb--wrap usa-breadcrumb--hack">
             
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/journals/2996/">Clin Transl Sci</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/issues/461639/">v.17(5); 2024 May</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC11116757
                </li>
            
    </ul>
 

        </div>
        
        
            <div class="pmc-sidebar pmc-sidebar-hack">
                

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC11116757/pdf/CTS-17-e13828.pdf" class="int-view">PDF (3.8M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/11116757/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/11116757/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="11116757" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC11116757%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="MUwiGn2d5D94sC2YjPCziUF6f3jWuEvBrd0tns3fJHEmEgDqYZthGdeWgiDwBwuJ">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-header "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-header ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-header "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-header ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC11116757%2F&amp;text=Metabolomic%20signatures%20of%20carfilzomib%02010related%20cardiotoxicity%20in%20patients%20with%20multiple%20myeloma" alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC11116757%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11116757/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC11116757/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/38783568/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-header" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC11116757/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/38783568/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-header"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC11116757/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/11116757/" class="usa-accordion-content" id="links-accordion-header" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>
            </div>
        

    </nav>

</header>

    
    

    <div class="usa-overlay"></div>
    
<main id="main-content" class="usa-grid usa-layout-docs pmc-main">
    <article class="usa-width-three-fourths usa-layout-docs-main_content pmc-article">
        <section class="usa-breadcrumb usa-breadcrumb--wrap">
         
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/journals/2996/">Clin Transl Sci</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/issues/461639/">v.17(5); 2024 May</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC11116757
                </li>
            
    </ul>
 

        </section>
        
  <div class="pmc-article__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/pmc/about/disclaimer/">PMC Disclaimer</a>
    |
    <a data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/pmc/about/copyright/">
        PMC Copyright Notice
    </a>
</div>

        <section class="pmc-page-banner" role="banner">
            
                
                    <div><img src="/corehtml/pmc/pmcgifs/logo-cts.gif" alt="Logo of cts" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher's site" title="Link to Publisher's site" shape="default" coords="0,0,499,74" href="http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1752-8062" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /></map></div> 
                
            
        </section>
        <section  role="document">
            
                <div id="mc" class=" article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden,.nomenu'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-flexbox"><div class="fm-citation"><div class="citation-default"><div class="part1"><span id="pmcmata">Clin Transl Sci.</span> 2024 May; 17(5): e13828. </div><div class="part2"><span class="fm-vol-iss-date">Published online 2024 May 23. </span>  <span class="doi"><span>doi: </span><a href="//doi.org/10.1111%2Fcts.13828" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1111/cts.13828</a></span></div></div></div><div class="fm-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC11116757</span></div><div class="fm-citation-pmid">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/38783568">38783568</a></div></div></div><h1 class="content-title">Metabolomic signatures of carfilzomib&#x02010;related cardiotoxicity in patients with multiple myeloma</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Shabnaz%20S%5BAuthor%5D" id="cts13828-cr-0001" class="affpopup" co-rid="_co_idm140308754006832" co-class="co-affbox">Samia Shabnaz</a>,<sup>
1
</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Nguyen%20TN%5BAuthor%5D" id="cts13828-cr-0002" class="affpopup" co-rid="_co_idm140308754003488" co-class="co-affbox">Trang N. Nguyen</a>,<sup>
1
</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Williams%20R%5BAuthor%5D" id="cts13828-cr-0003" class="affpopup" co-rid="_co_idm140308754000144" co-class="co-affbox">Roy Williams</a>,<sup>
1
</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Rubinstein%20SM%5BAuthor%5D" id="cts13828-cr-0004" class="affpopup" co-rid="_co_idm140308753996800" co-class="co-affbox">Samuel M. Rubinstein</a>,<sup>
2
</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Garrett%20TJ%5BAuthor%5D" id="cts13828-cr-0005" class="affpopup" co-rid="_co_idm140308753993456" co-class="co-affbox">Timothy J. Garrett</a>,<sup>
3
</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Tantawy%20M%5BAuthor%5D" id="cts13828-cr-0006" class="affpopup" co-rid="_co_idm140308747909536" co-class="co-affbox">Marwa Tantawy</a>,<sup>
1
</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Fradley%20MG%5BAuthor%5D" id="cts13828-cr-0007" class="affpopup" co-rid="_co_idm140308747906192" co-class="co-affbox">Michael G. Fradley</a>,<sup>
4
</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Alomar%20ME%5BAuthor%5D" id="cts13828-cr-0008" class="affpopup" co-rid="_co_idm140308747903584" co-class="co-affbox">Mohammed E. Alomar</a>,<sup>
5
</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Shain%20KH%5BAuthor%5D" id="cts13828-cr-0009" class="affpopup" co-rid="_co_idm140308747900240" co-class="co-affbox">Kenneth H. Shain</a>,<sup>
5
</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Baz%20RC%5BAuthor%5D" id="cts13828-cr-0010" class="affpopup" co-rid="_co_idm140308747896896" co-class="co-affbox">Rachid C. Baz</a>,<sup>
5
</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Lenihan%20D%5BAuthor%5D" id="cts13828-cr-0011" class="affpopup" co-rid="_co_idm140308747893552" co-class="co-affbox">Daniel Lenihan</a>,<sup>
6
</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Cornell%20RF%5BAuthor%5D" id="cts13828-cr-0012" class="affpopup" co-rid="_co_idm140308755522656" co-class="co-affbox">Robert F. Cornell</a>,<sup>
7
</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Lu%20Q%5BAuthor%5D" id="cts13828-cr-0013" class="affpopup" co-rid="_co_idm140308755519312" co-class="co-affbox">Qing Lu</a>,<sup>
8
</sup> and  <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Gong%20Y%5BAuthor%5D" id="cts13828-cr-0014" class="affpopup" co-rid="_co_idm140308755515968" co-class="co-affbox">Yan Gong</a><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup><sup>
1
,</sup><sup>
9
</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm140308754006832"><h3 class="no_margin">Samia Shabnaz</h3><p>
<sup>
1
</sup>
Department of Pharmacotherapy and Translational Research, 
Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, 
University of Florida, 
Gainesville
Florida, 
USA
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Shabnaz%20S%5BAuthor%5D">Samia Shabnaz</a></div></div><div id="_co_idm140308754003488"><h3 class="no_margin">Trang N. Nguyen</h3><p>
<sup>
1
</sup>
Department of Pharmacotherapy and Translational Research, 
Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, 
University of Florida, 
Gainesville
Florida, 
USA
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Nguyen%20TN%5BAuthor%5D">Trang N. Nguyen</a></div></div><div id="_co_idm140308754000144"><h3 class="no_margin">Roy Williams</h3><p>
<sup>
1
</sup>
Department of Pharmacotherapy and Translational Research, 
Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, 
University of Florida, 
Gainesville
Florida, 
USA
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Williams%20R%5BAuthor%5D">Roy Williams</a></div></div><div id="_co_idm140308753996800"><h3 class="no_margin">Samuel M. Rubinstein</h3><p>
<sup>
2
</sup>
Department of Medicine, Division of Hematology, 
University of North Carolina, 
Chapel Hill
North Carolina, 
USA
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Rubinstein%20SM%5BAuthor%5D">Samuel M. Rubinstein</a></div></div><div id="_co_idm140308753993456"><h3 class="no_margin">Timothy J. Garrett</h3><p>
<sup>
3
</sup>
Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, 
University of Florida, 
Gainesville
Florida, 
USA
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Garrett%20TJ%5BAuthor%5D">Timothy J. Garrett</a></div></div><div id="_co_idm140308747909536"><h3 class="no_margin">Marwa Tantawy</h3><p>
<sup>
1
</sup>
Department of Pharmacotherapy and Translational Research, 
Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, 
University of Florida, 
Gainesville
Florida, 
USA
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Tantawy%20M%5BAuthor%5D">Marwa Tantawy</a></div></div><div id="_co_idm140308747906192"><h3 class="no_margin">Michael G. Fradley</h3><p>
<sup>
4
</sup>
Cardio&#x02010;Oncology Center of Excellence, Division of Cardiology, Department of Medicine, 
Perelman School of Medicine at the University of Pennsylvania, 
Philadelphia
Pennsylvania, 
USA
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Fradley%20MG%5BAuthor%5D">Michael G. Fradley</a></div></div><div id="_co_idm140308747903584"><h3 class="no_margin">Mohammed E. Alomar</h3><p>
<sup>
5
</sup>
Department of Malignant Hematology, 
H. Lee Moffitt Cancer Center &#x00026; Research Institute, 
Tampa
Florida, 
USA
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Alomar%20ME%5BAuthor%5D">Mohammed E. Alomar</a></div></div><div id="_co_idm140308747900240"><h3 class="no_margin">Kenneth H. Shain</h3><p>
<sup>
5
</sup>
Department of Malignant Hematology, 
H. Lee Moffitt Cancer Center &#x00026; Research Institute, 
Tampa
Florida, 
USA
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Shain%20KH%5BAuthor%5D">Kenneth H. Shain</a></div></div><div id="_co_idm140308747896896"><h3 class="no_margin">Rachid C. Baz</h3><p>
<sup>
5
</sup>
Department of Malignant Hematology, 
H. Lee Moffitt Cancer Center &#x00026; Research Institute, 
Tampa
Florida, 
USA
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Baz%20RC%5BAuthor%5D">Rachid C. Baz</a></div></div><div id="_co_idm140308747893552"><h3 class="no_margin">Daniel Lenihan</h3><p>
<sup>
6
</sup>
Cape Cardiology Group, 
Saint Francis Medical Center, 
Cape Girardeau
Missouri, 
USA
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Lenihan%20D%5BAuthor%5D">Daniel Lenihan</a></div></div><div id="_co_idm140308755522656"><h3 class="no_margin">Robert F. Cornell</h3><p>
<sup>
7
</sup>
Department of Medicine, Division of Hematology and Oncology, 
Vanderbilt University Medical Center, 
Nashville
Tennessee, 
USA
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Cornell%20RF%5BAuthor%5D">Robert F. Cornell</a></div></div><div id="_co_idm140308755519312"><h3 class="no_margin">Qing Lu</h3><p>
<sup>
8
</sup>
Department of Biostatistics, College of Public Health and Health Professions &#x00026; College of Medicine, 
University of Florida, 
Gainesville
Florida, 
USA
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Lu%20Q%5BAuthor%5D">Qing Lu</a></div></div><div id="_co_idm140308755515968"><h3 class="no_margin">Yan Gong</h3><p>
<sup>
1
</sup>
Department of Pharmacotherapy and Translational Research, 
Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, 
University of Florida, 
Gainesville
Florida, 
USA
</p><p>
<sup>
9
</sup>
Cardio&#x02010;Oncology Working Group, 
UF Health Cancer Center, 
Gainesville
Florida, 
USA
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Gong%20Y%5BAuthor%5D">Yan Gong</a></div></div></div></div><div class="half_rhythm"><div class="togglers fm-copyright-license"><a href="#" class="pmctoggle" rid="idm140308748445856_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140308748445856_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm140308748445856_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/" style="margin-left: 1em">PMC Disclaimer</a></div><div class="fm-authors-info hide half_rhythm" id="idm140308748445856_ai" style="display:none"><div class="fm-affl" id="cts13828-aff-0001">
<sup>
1
</sup>
Department of Pharmacotherapy and Translational Research, 
Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, 
University of Florida, 
Gainesville
Florida, 
USA
</div><div class="fm-affl" id="cts13828-aff-0002">
<sup>
2
</sup>
Department of Medicine, Division of Hematology, 
University of North Carolina, 
Chapel Hill
North Carolina, 
USA
</div><div class="fm-affl" id="cts13828-aff-0003">
<sup>
3
</sup>
Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, 
University of Florida, 
Gainesville
Florida, 
USA
</div><div class="fm-affl" id="cts13828-aff-0004">
<sup>
4
</sup>
Cardio&#x02010;Oncology Center of Excellence, Division of Cardiology, Department of Medicine, 
Perelman School of Medicine at the University of Pennsylvania, 
Philadelphia
Pennsylvania, 
USA
</div><div class="fm-affl" id="cts13828-aff-0005">
<sup>
5
</sup>
Department of Malignant Hematology, 
H. Lee Moffitt Cancer Center &#x00026; Research Institute, 
Tampa
Florida, 
USA
</div><div class="fm-affl" id="cts13828-aff-0006">
<sup>
6
</sup>
Cape Cardiology Group, 
Saint Francis Medical Center, 
Cape Girardeau
Missouri, 
USA
</div><div class="fm-affl" id="cts13828-aff-0007">
<sup>
7
</sup>
Department of Medicine, Division of Hematology and Oncology, 
Vanderbilt University Medical Center, 
Nashville
Tennessee, 
USA
</div><div class="fm-affl" id="cts13828-aff-0008">
<sup>
8
</sup>
Department of Biostatistics, College of Public Health and Health Professions &#x00026; College of Medicine, 
University of Florida, 
Gainesville
Florida, 
USA
</div><div class="fm-affl" id="cts13828-aff-0009">
<sup>
9
</sup>
Cardio&#x02010;Oncology Working Group, 
UF Health Cancer Center, 
Gainesville
Florida, 
USA
</div><div><span class="fm-affl">Yan Gong, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.lfu.poc@gnog" class="oemail">ude.lfu.poc@gnog</a></span>.</div><div><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup>Corresponding author.</div><div id="correspondenceTo"><sup>*</sup>

<strong>Correspondence</strong>
<br />
Yan Gong, Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, PO Box&#x000a0;100486, 1345 Center Drive, Gainesville, FL 32610&#x02010;0486, USA.<br />
Email: <a href="mailto:dev@null" data-email="ude.lfu.poc@gnog" class="oemail">ude.lfu.poc@gnog</a>
<br />
</div></div><div class="fm-article-notes hide half_rhythm" id="idm140308748445856_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2024 Jan 12; Revised 2024 Apr 12; Accepted 2024 May 3.</div></div><div class="permissions half_rhythm hide" id="idm140308748445856_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a> &#x000a9; 2024 The Author(s). <em>Clinical and Translational Science</em> published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</div><div class="license half_rhythm">This is an open access article under the terms of the <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CFront%20Matter&amp;TO=External%7CLink%7CURI" target="_blank">http://creativecommons.org/licenses/by-nc-nd/4.0/</a> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm hidden" role="complementary" aria-label="Related or updated information about this article."></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><h2 class="nomenu">Associated Data</h2><dl data-count="1" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin">
Appendix S1.
</div><div><a href="/pmc/articles/PMC11116757/bin/CTS-17-e13828-s001.docx" data-ga-action="click_feat_suppl">CTS-17-e13828-s001.docx</a><span style="color:gray"> (35K)</span></div><div class="small guid">GUID: A7E997AE-B1AF-456F-9EDE-7E2462B08CA3</div></div></dd></dl></div><div id="abstract-a.k.b.z" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="abstract-a.k.b.ztitle">Abstract</h2><!--article-meta--><div><p class="p p-first-last">As a treatment for relapsed or refractory multiple myeloma (MM), carfilzomib has been associated with a significant risk of cardiovascular adverse events (CVAE). The goals of our study were to evaluate the metabolomic profile of MM patients to identify those at high risk prior to carfilzomib treatment and to explore the mechanisms of carfilzomib&#x02010;CVAE to inform potential strategies to protect patients from this cardiotoxicity. Global metabolomic profiling was performed on the baseline and post&#x02010;baseline plasma samples of 60&#x02009;MM patients treated with carfilzomib&#x02010;based therapy, including 31 who experienced CVAE, in a prospective cohort study. Baseline metabolites and post&#x02010;baseline/baseline metabolite ratios that differ between the CVAE and no&#x02010;CVAE patients were identified using unadjusted and adjusted methods. A baseline metabolomic risk score was created to stratify patients. We observed a lower abundance of tauroursodeoxycholic acid (T&#x02010;UDCA) in CVAE patients at baseline (odds ratio [OR]&#x02009;=&#x02009;0.47, 95% confidence interval [CI]&#x02009;=&#x02009;0.21&#x02013;0.94, <em>p</em>&#x02009;=&#x02009;0.044) compared with the no&#x02010;CVAE patients. A metabolite risk score was able to stratify patients into three risk groups. The area under the receiver&#x02010;operating curve of the model with clinical predictors and metabolite risk score was 0.93. Glycochenodeoxycholic acid (OR&#x02009;=&#x02009;0.56, 95% CI&#x02009;=&#x02009;0.31&#x02013;0.87, <em>p</em>&#x02009;=&#x02009;0.023) was significantly lower in post&#x02010;baseline/baseline ratios of CVAE patients compared with no&#x02010;CVAE patients. Following metabolomic analysis, we created a baseline metabolite risk score that can stratify MM patients into different risk groups. The result also provided intriguing clues about the mechanism of carfilzomib&#x02010;CVAE and potential cardioprotective strategies.</p></div></div><div id="cts13828-body-0001" class="tsec sec"><h2 class="headless nomenu"></h2><div class="def-list" id="cts13828-dl-0001"><h4>Abbreviations</h4><dl class="labeled-list"><dt id="cts13828-li-0005">AUC&#x02010;ROC</dt><dd id="cts13828-li-0006">Area under the receiver&#x02010;operating curve</dd><dt id="cts13828-li-0007">BNP</dt><dd id="cts13828-li-0008">Brain natriuretic peptide</dd><dt id="cts13828-li-0009">CVAE</dt><dd id="cts13828-li-0010">Cardiovascular adverse events</dd><dt id="cts13828-li-0011">GCA</dt><dd id="cts13828-li-0012">Glycocholic acid</dd><dt id="cts13828-li-0013">HF</dt><dd id="cts13828-li-0014">Heart failure</dd><dt id="cts13828-li-0015">MM</dt><dd id="cts13828-li-0016">Multiple myeloma</dd><dt id="cts13828-li-0017">MRS</dt><dd id="cts13828-li-0018">Metabolite risk score</dd><dt id="cts13828-li-0019">NT&#x02010;proBNP</dt><dd id="cts13828-li-0020">N&#x02010;terminal proBNP</dd><dt id="cts13828-li-0021">TCA</dt><dd id="cts13828-li-0022">Taurocholic acid</dd><dt id="cts13828-li-0023">T&#x02010;UDCA</dt><dd id="cts13828-li-0024">Tauroursodeoxycholic acid</dd></dl></div><p class="p">
</p><div class="boxed-text-box whole_rhythm hide-overflow"><div class="caption"><h3 id="caption-a.l.b.a.atitle">Study Highlights</h3></div><p>
</p><ul class="simple" style="list-style-type:none" id="cts13828-list-0001"><li id="cts13828-li-0001"><div>
<strong>WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?</strong>
</div></li></ul><p>
</p><p>Current risk stratification of MM patients taking carfilzomib involves regular observation of the patients to monitor CVAE rather than proactively stratifying patients using clinical variables and biomarkers. There has been no study on baseline biomarkers of carfilzomib&#x02010;CVAE in MM patients.
</p><ul class="simple" style="list-style-type:none" id="cts13828-list-0002"><li id="cts13828-li-0002"><div>
<strong>WHAT QUESTION DID THIS STUDY ADDRESS?</strong>
</div></li></ul><p>
</p><p>Metabolomic profiling of MM patients was conducted to better understand the intricate mechanism and predictive biomarkers for carfilzomib&#x02010;CVAE. Our study intended to provide essential information to stratify patients and for a better understanding of the underlying mechanisms of carfilzomib&#x02010;CVAE.
</p><ul class="simple" style="list-style-type:none" id="cts13828-list-0003"><li id="cts13828-li-0003"><div>
<strong>WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?</strong>
</div></li></ul><p>
</p><p>MM patients who developed carfilzomib&#x02010;CVAE appeared to have a lower abundance of bile acid T&#x02010;UDCA at baseline and post&#x02010;baseline. A risk score based on pretreatment metabolite levels was established to stratify patients with MM into different risk groups for carfilzomib&#x02010;CVAE. This model outperformed models with clinical predictors alone.
</p><ul class="simple" style="list-style-type:none" id="cts13828-list-0004"><li id="cts13828-li-0004"><div>
<strong>HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?</strong>
</div></li></ul><p>
</p><p>If validated in an independent cohort, our model will enable us to identify MM patients at an increased risk of CVAE prior to carfilzomib treatment so that preventive measures can be taken. The identified metabolites also provided some intriguing clues about the mechanism of carfilzomib&#x02010;CVAE and potential cardioprotective strategies for future investigation.</p></div><p>
</p></div><div id="cts13828-sec-0003" class="tsec sec"><h2 class="head no_bottom_margin" id="cts13828-sec-0003title">INTRODUCTION</h2><p class="p p-first">Multiple myeloma (MM) is a cancer of plasma cells and is the second most common hematologic cancer in the United States.<sup><a href="#cts13828-bib-0001" rid="cts13828-bib-0001" class=" bibr popnode">
1
</a></sup> Proteasome inhibitors are one of the most important drug classes for the treatment of MM that emerged in the past two decades and are now the backbones of MM treatment.<sup><a href="#cts13828-bib-0002" rid="cts13828-bib-0002" class=" bibr popnode">
2
</a></sup> Carfilzomib is a second&#x02010;generation, irreversible proteasome inhibitor approved for the treatment of relapsed/refractory MM due to its survival benefit and overall response rate in pretreated MM patients.<sup><a href="#cts13828-bib-0003" rid="cts13828-bib-0003" class=" bibr popnode">
3
</a></sup><sup>, </sup><sup><a href="#cts13828-bib-0004" rid="cts13828-bib-0004" class=" bibr popnode">
4
</a></sup><sup>, </sup><sup><a href="#cts13828-bib-0005" rid="cts13828-bib-0005" class=" bibr popnode">
5
</a></sup> Despite its effectiveness, carfilzomib has been associated with significant cardiovascular adverse events (CVAE), such as hypertension, heart failure, and arrhythmias, with reported incidence ranging from 8% to 18%.<sup><a href="#cts13828-bib-0002" rid="cts13828-bib-0002" class=" bibr popnode">
2
</a></sup><sup>, </sup><sup><a href="#cts13828-bib-0006" rid="cts13828-bib-0006" class=" bibr popnode">
6
</a></sup> The event rate is even higher in observational studies because of the fact that patients with existing significant cardiovascular disease are not excluded. For example, the prospective study of cardiac events during proteasome inhibitor therapy (PROTECT) study reported that 51% of the MM patients developed carfilzomib&#x02010;CVAE.<sup><a href="#cts13828-bib-0007" rid="cts13828-bib-0007" class=" bibr popnode">
7
</a></sup>
</p><p>Carfilzomib&#x02010;CVAE has been recognized as a significant clinical problem that increases the long&#x02010;term mortality of MM patients. Patients who experienced a CVAE had significantly inferior progression&#x02010;free survival and overall survival compared with patients not experiencing a CVAE.<sup><a href="#cts13828-bib-0007" rid="cts13828-bib-0007" class=" bibr popnode">
7
</a></sup> Recently, the 2022 Cardio&#x02010;Oncology guideline developed by the European Society of Cardiology (ESC), in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO), and the International Cardio&#x02010;Oncology society (IC&#x02010;OS), recommends stratifying patients based on CVAE risk before anticancer therapy, including proteasome inhibitors. So far, the only confirmed clinical risk factor for risk stratification for MM patients prior to carfilzomib treatment is the natriuretic peptides.<sup><a href="#cts13828-bib-0007" rid="cts13828-bib-0007" class=" bibr popnode">
7
</a></sup>
</p><p>Our previous multi&#x02010;omic integrative analysis of 13&#x02009;MM patients treated with carfilzomib showed that patients with CVAE had lower levels of pyruvate and higher levels of lactate dehydrogenase B compared with those without CVAE. These findings suggested that the pyruvate oxidation pathway associated with mitochondrial dysfunction might be important for the development of carfilzomib&#x02010;CVAE.<sup><a href="#cts13828-bib-0008" rid="cts13828-bib-0008" class=" bibr popnode">
8
</a></sup> Even though this pilot study indicated the feasibility and importance of investigating the plasma metabolome, we were not able to predict which patients were at high risk of developing carfilzomib&#x02010;CVAE due to the lack of baseline samples.</p><p class="p p-last">For this current prospective study, we hypothesized that MM patients at high risk for carfilzomib&#x02010;CVAE had different baseline metabolomic profiles compared with those at a lower risk for this toxicity and that the metabolites change before and after the carfilzomib treatment will inform the underlying mechanisms of the development of carfilzomib&#x02010;CVAE. The goal of this study was to evaluate the baseline and post&#x02010;baseline metabolomic profiles of patients treated with carfilzomib to identify those at high risk for carfilzomib&#x02010;CVAE before the treatment and to discern the potential mechanisms for such toxicity to inform future cardioprotective strategies.</p></div><div id="cts13828-sec-0004" class="tsec sec"><h2 class="head no_bottom_margin" id="cts13828-sec-0004title">METHODS</h2><div id="cts13828-sec-0005" class="sec sec-first"><h3 id="cts13828-sec-0005title">Patients</h3><p class="p p-first-last">The patients included in this study were from the PROTECT study, a prospective, observational multi&#x02010;institutional study,<sup><a href="#cts13828-bib-0007" rid="cts13828-bib-0007" class=" bibr popnode">
7
</a></sup> conducted at the Vanderbilt University Medical Center and the University of Pennsylvania Abramson Cancer Center between September 2015 and March 2018 to evaluate the risk factors and outcomes in patients with MM treated with carfilzomib&#x02010; or bortezomib&#x02010;based therapy. This study was approved by the Institutional Review Board of Vanderbilt University Medical Center and the University of Pennsylvania Abramson Cancer Center, and all human participants gave written informed consent.<sup><a href="#cts13828-bib-0007" rid="cts13828-bib-0007" class=" bibr popnode">
7
</a></sup> The details and the main findings of the PROTECT study have been published previously.<sup><a href="#cts13828-bib-0007" rid="cts13828-bib-0007" class=" bibr popnode">
7
</a></sup> Briefly, patients were included if they had relapsed MM, defined according to the International Myeloma Working Group criteria,<sup><a href="#cts13828-bib-0009" rid="cts13828-bib-0009" class=" bibr popnode">
9
</a></sup> and were initiating treatment with physician choice of carfilzomib&#x02010; or bortezomib&#x02010;based therapy. Patients with symptomatic cardiac arrhythmia or New York Heart Association Class 3 or 4 heart failure (HF) within 3&#x02009;months prior to enrollment or those with light chain amyloidosis were excluded.<sup><a href="#cts13828-bib-0007" rid="cts13828-bib-0007" class=" bibr popnode">
7
</a></sup> Enrolled patients underwent comprehensive baseline cardiovascular evaluations, including traditional cardiovascular risk factors (such as hypertension, hyperlipidemia, and diabetes), cardiac biomarkers (brain natriuretic peptide (BNP), or N&#x02010;terminal proBNP (NT&#x02010;proBNP), transthoracic echocardiography, and cardiologist evaluation). CVAE was diagnosed and adjudicated by a cardiologist with a specialty in Cardio&#x02010;Oncology. International Myeloma Working Group criteria were used to explain the advancement of MM.<sup><a href="#cts13828-bib-0009" rid="cts13828-bib-0009" class=" bibr popnode">
9
</a></sup> All CVAE were graded according to the Common Terminology Criteria for Adverse Events (version 4.03). The main findings of the PROTECT study were that the rate of CVAE was higher in relapsed MM patients treated with carfilzomib (51%) than bortezomib (17%), that most CVAE occurred within 3 months of the initiation of carfilzomib therapy, and that natriuretic peptides above normal (BNP&#x02009;&#x0003e;&#x02009;100&#x02009;pg/mL or NT&#x02010;proBNP &#x0003e;125&#x02009;pg/mL) were highly predictive of CVAE.<sup><a href="#cts13828-bib-0007" rid="cts13828-bib-0007" class=" bibr popnode">
7
</a></sup>
</p></div><div id="cts13828-sec-0006" class="sec"><h3 id="cts13828-sec-0006title">Plasma samples</h3><p class="p p-first-last">In the PROTECT study, plasma samples were collected and stored at baseline and then every cycle (every 3&#x02013;4&#x02009;weeks) while on treatment for up to 6&#x02009;months. Patients were then clinically observed for the development of CVAE for an additional 12&#x02009;months. The current study evaluated the baseline and post&#x02010;baseline plasma samples from 60 patients treated with a carfilzomib&#x02010;based regimen. Patients experiencing a CVAE during treatment had an additional plasma sample collected at the visit when CVAE was diagnosed as part of the PROTECT protocol, and these samples were analyzed as the post&#x02010;baseline samples. Since all the CVAE occurred within 6&#x02009;months of initiation of carfilzomib therapy, for patients who did not experience CVAE during the study, the plasma samples at the 6&#x02010;month visits were analyzed as the post&#x02010;baseline samples.</p></div><div id="cts13828-sec-0007" class="sec"><h3 id="cts13828-sec-0007title">Global metabolomic profiling</h3><p class="p p-first-last">Global metabolomic profiling was performed on the baseline and post&#x02010;baseline plasma samples of the 60 PROTECT patients by using a Thermo Q&#x02010;Exactive Orbitrap mass spectrometer coupled with ultra&#x02010;high&#x02010;performance liquid chromatography at the Southeast Center for Integrated Metabolomics at the University of Florida.<sup><a href="#cts13828-bib-0010" rid="cts13828-bib-0010" class=" bibr popnode">
10
</a></sup> All samples were analyzed in positive and negative heated electrospray ionization with a mass resolution of 35,000. The metabolite data went through a rigorous quality assessment before data analyses. MZmine2 software<sup><a href="#cts13828-bib-0011" rid="cts13828-bib-0011" class=" bibr popnode">
11
</a></sup> was used for peak detection and peak identification through an internal database and online databases, such as PubChem,<sup><a href="#cts13828-bib-0012" rid="cts13828-bib-0012" class=" bibr popnode">
12
</a></sup> KEGG,<sup><a href="#cts13828-bib-0013" rid="cts13828-bib-0013" class=" bibr popnode">
13
</a></sup> METLIN<sup><a href="#cts13828-bib-0014" rid="cts13828-bib-0014" class=" bibr popnode">
14
</a></sup> or HMDB,<sup><a href="#cts13828-bib-0015" rid="cts13828-bib-0015" class=" bibr popnode">
15
</a></sup> deisotope and align features. We used blank feature filtering to remove metabolites that were below the lower limits of quantification handled.<sup><a href="#cts13828-bib-0016" rid="cts13828-bib-0016" class=" bibr popnode">
16
</a></sup> The internal metabolite database was curated using authentic standards. We searched with a mass accuracy of 5&#x02009;ppm in positive ion mode and 10&#x02009;ppm in negative ion mode and a retention time accuracy of &#x000b1;0.2&#x02009;min. These represent level 1 identified metabolites and are identified in all caps. For additional identifications, we searched the HMDB<sup><a href="#cts13828-bib-0015" rid="cts13828-bib-0015" class=" bibr popnode">
15
</a></sup> with a mass tolerance of 5&#x02009;ppm (positive) and 10&#x02009;ppm (negative), which represent level 3 identified metabolites and are in lowercase when identified. The normality of the peak intensity data for each metabolite was assessed by evaluating the intensity distribution following normalization to sum, log transformation, and autoscaling (mean&#x02010;centered and divided by the standard deviation of each metabolite) using MetaboAnalyst 5.0<sup><a href="#cts13828-bib-0017" rid="cts13828-bib-0017" class=" bibr popnode">
17
</a></sup> prior to statistical analyses. The peak intensity data analysis was analyzed for CVAE, HF, and hypertension. Because this platform provides a relative abundance of the metabolites, but not exact concentrations of the metabolites, the ratios of the peak intensity of post&#x02010;baseline/baseline of each metabolite were calculated for each patient to evaluate the changes in metabolites before and after carfilzomib treatment.</p></div><div id="cts13828-sec-0008" class="sec"><h3 id="cts13828-sec-0008title">Statistical analysis</h3><p class="p p-first-last">Demographic and clinical characteristics were summarized and compared between those who developed CVAE vs. those who did not develop CVAE (no&#x02010;CVAE) using Chi&#x02010;square or Fisher's exact test for categorical variables and <em>t</em>&#x02010;test or Wilcoxon rank&#x02010;sum test for continuous variables as appropriate. The baseline metabolites that differ in CVAE and no&#x02010;CVAE patients were identified through univariate analysis using MetaboAnalyst 5.0.<sup><a href="#cts13828-bib-0017" rid="cts13828-bib-0017" class=" bibr popnode">
17
</a></sup> The metabolites with fold change &#x02265;1.5 or &#x02264;0.67 and <em>p</em>&#x02009;&#x0003c;&#x02009;0.05 in <em>t</em>&#x02010;test were considered nominally significant, and the metabolites with false discovery rate (FDR)&#x02009;&#x0003c;&#x02009;0.05 were considered statistically significant. Least absolute shrinkage and selection operator (LASSO) Cox regression<sup><a href="#cts13828-bib-0018" rid="cts13828-bib-0018" class=" bibr popnode">
18
</a></sup> was used to select a predictive model with relevant baseline metabolites and clinical variables. A metabolite risk score (MRS) was calculated to combine the selected baseline metabolites weighted by the beta&#x02010;coefficients by summing the products of the normalized intensity of each top baseline metabolite and its beta&#x02010;coefficient estimated from the LASSO Cox regression. The tertile of MRS was used to stratify patients into low&#x02010;, intermediate&#x02010;, and high&#x02010;risk groups. Kaplan&#x02013;Meier curve and log&#x02010;rank test were performed to compare the time&#x02010;to&#x02010;CVAE of these three groups. The area under the receiver&#x02010;operating curve (AUC&#x02010;ROC) was calculated to measure the performance of the models. The differences between the AUC&#x02010;ROC of different models were tested using Delong's statistic.<sup><a href="#cts13828-bib-0019" rid="cts13828-bib-0019" class=" bibr popnode">
19
</a></sup> To evaluate the effect of carfilzomib treatment on the metabolomic profile, the ratio of post&#x02010;baseline/baseline peak intensity levels of the metabolites was assessed. <em>t</em>&#x02010;test was performed by using MetaboAnalyst 5.0.<sup><a href="#cts13828-bib-0017" rid="cts13828-bib-0017" class=" bibr popnode">
17
</a></sup> Stepwise multivariable logistic regression was performed by using SAS v 9.4 (Cary, NC, USA)<sup><a href="#cts13828-bib-0020" rid="cts13828-bib-0020" class=" bibr popnode">
20
</a></sup> and LASSO Cox regression was performed in R statistical software version 4.22 with package glmnet.</p></div><div id="cts13828-sec-0009" class="sec sec-last"><h3 id="cts13828-sec-0009title">Pathway analysis</h3><p class="p p-first-last">Ingenuity Pathway Analysis version 6.0 (IPA&#x000ae;, QIAGEN Bioinformatics, CA, USA) was used to explore the canonical pathways and the over&#x02010;representation of pathways using the significant metabolites. Fisher's exact test was used to evaluate the enrichment of pathways based on the significant metabolites.<sup><a href="#cts13828-bib-0021" rid="cts13828-bib-0021" class=" bibr popnode">
21
</a></sup> The null hypothesis is that there is no enrichment of any metabolites in a particular pathway. A <em>p</em>&#x02010;value &#x0003c;0.05 indicates that a metabolite occurs in a particular pathway more frequently than by chance.</p></div></div><div id="cts13828-sec-0010" class="tsec sec"><h2 class="head no_bottom_margin" id="cts13828-sec-0010title">RESULTS</h2><div id="cts13828-sec-0011" class="sec sec-first"><h3 id="cts13828-sec-0011title">Patient characteristics</h3><p class="p p-first">The overall median age of these 60 patients with MM treated with carfilzomib was 68&#x02009;years and 75% were men and 87% were white. Among these patients, 31 (52%) developed different types of CVAE, including 16 (26.67%) who developed congestive HF and 11 (18.33%) with grade 3 or 4 hypertension. In addition, 3 (5%) patients developed arrhythmia, acute coronary syndrome, or pulmonary hypertension. The baseline demographics or medical history were not statistically different between the patients who developed CVAE compared with those who did not, except that higher percentages of patients in the CVAE group (18%) had baseline BNP or NT&#x02010;proBNP above the cutoff levels (BNP&#x02009;&#x0003e;100&#x02009;pg/mL or NT&#x02010;proBNP &#x0003e;125&#x02009;pg/mL) than those who did not develop CVAE (4%) (<em>p</em>&#x02009;=&#x02009;0.0004) (Table&#x000a0;<a href="/pmc/articles/PMC11116757/table/cts13828-tbl-0001/" target="table" class="fig-table-link figpopup" rid-figpopup="cts13828-tbl-0001" rid-ob="ob-cts13828-tbl-0001" co-legend-rid=""><span>1</span></a>).</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="cts13828-tbl-0001"><h3>TABLE 1</h3><!--caption a7--><div class="caption"><p>Baseline characteristics of patients.</p></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Characteristics</th><th align="left" valign="bottom" rowspan="1" colspan="1">CVAE (<em>n</em>&#x02009;=&#x02009;31)</th><th align="left" valign="bottom" rowspan="1" colspan="1">No&#x02010;CVAE (<em>n</em>&#x02009;=&#x02009;29)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<em>p</em>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="center" valign="top" rowspan="1" colspan="1">68 (11)</td><td align="center" valign="top" rowspan="1" colspan="1">67 (14)</td><td align="center" valign="top" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex (Male)</td><td align="center" valign="top" rowspan="1" colspan="1">23 (74.19)</td><td align="center" valign="top" rowspan="1" colspan="1">22 (75.86)</td><td align="center" valign="top" rowspan="1" colspan="1">0.88</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Race</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;0.99</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">White</td><td align="center" valign="top" rowspan="1" colspan="1">27 (87.10)</td><td align="center" valign="top" rowspan="1" colspan="1">25 (86.21)</td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Black</td><td align="center" valign="top" rowspan="1" colspan="1">4 (12.90)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (13.79)</td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Smoker</td><td align="center" valign="top" rowspan="1" colspan="1">15 (48.39)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (37.93)</td><td align="center" valign="top" rowspan="1" colspan="1">0.41</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NYHA</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">18 (58.06)</td><td align="center" valign="top" rowspan="1" colspan="1">18 (62.07)</td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">13 (41.94)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (37.93)</td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hypertension</td><td align="center" valign="top" rowspan="1" colspan="1">15 (48.39)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (27.59)</td><td align="center" valign="top" rowspan="1" colspan="1">0.10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Family history of CVD</td><td align="center" valign="top" rowspan="1" colspan="1">19 (61.29)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (51.72)</td><td align="center" valign="top" rowspan="1" colspan="1">0.45</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diabetes mellitus</td><td align="center" valign="top" rowspan="1" colspan="1">4 (12.90)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (13.79)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;0.99</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hypercholesterolemia</td><td align="center" valign="top" rowspan="1" colspan="1">8 (25.81)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (37.93)</td><td align="center" valign="top" rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Thrombosis</td><td align="center" valign="top" rowspan="1" colspan="1">6 (19.35)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (13.79)</td><td align="center" valign="top" rowspan="1" colspan="1">0.73</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Arrhythmia</td><td align="center" valign="top" rowspan="1" colspan="1">6 (19.35)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (13.79)</td><td align="center" valign="top" rowspan="1" colspan="1">0.73</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BNP above cutoff<sup>
a
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">18 (58.06)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (13.79)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0004</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Baseline LVEF<sup>
b
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">60 (8)</td><td align="center" valign="top" rowspan="1" colspan="1">64 (10)</td><td align="center" valign="top" rowspan="1" colspan="1">0.17</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm140308748548992"><a target="object" rel="noopener" href="/pmc/articles/PMC11116757/table/cts13828-tbl-0001/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="cts13828-note-0001"><p class="p p-first-last">
<em>Note</em>: Continuous variables are summarized as median and interquartile range. Categorical variables are summarized as <em>n</em> (%). <em>P</em>&#x02010;values for the categorical variables were determined using the Chi&#x02010;square or Fisher's exact test as appropriate. <em>P</em>&#x02010;values for the continuous variables were determined by Wilcoxon Rank&#x02010;Sum Test.</p></div><div id="cts13828-note-0002"><p class="p p-first-last">Abbreviations: CVAE, cardiovascular adverse events; NYHA, New York Heart Association Classification of Heart Failure.</p></div><div id="cts13828-note-0003"><sup>
a
</sup>BNP above cutoff: the binary indicator of whether the baseline BNP or NT&#x02010;proBNP was above the cutoff at diagnosis (BNP&#x02009;&#x0003e;&#x02009;100&#x02009;pg/mL or NT&#x02010;proBNP &#x0003e;125&#x02009;pg/mL).</div><div id="cts13828-note-0004"><sup>
b
</sup>Left Ventricular Ejection Fraction before carfilzomib treatment.</div></div></div></div><div id="cts13828-sec-0012" class="sec"><h3 id="cts13828-sec-0012title">Global metabolomics results</h3><p class="p p-first-last">A total of 13,911 metabolites were analyzed and among those, 570 unique known metabolites passed the quality control steps and were annotated by using MetaboAnalyst. The normalized peak intensity data of these metabolites were included in the metabolomic profiling analyses.</p></div><div id="cts13828-sec-0013" class="sec"><h3 id="cts13828-sec-0013title">Baseline metabolomic profiles</h3><p class="p p-first">In the unadjusted univariate analysis using <em>t</em>&#x02010;test to compare the peak intensity of each metabolite between the CVAE vs. no&#x02010;CVAE patients, 28 known baseline metabolites had a <em>p</em>&#x02009;&#x0003c;&#x02009;0.05 and fold change &#x02265;1.5 or &#x02264;0.67 between the two groups (Table&#x000a0;<a href="#cts13828-supitem-0001" rid="cts13828-supitem-0001" class=" supplementary-material">S1</a>). A few bile acids had lower levels in the patients who developed CVAE compared with those who did not. The level of glycocholic acid (GCA) was significantly lower in the baseline plasma of patients who experienced CVAE compared with those who did not develop CVAE (fold change&#x02009;=&#x02009;0.28, <em>p</em>&#x02009;=&#x02009;0.0002, FDR adjusted <em>p</em>&#x02009;=&#x02009;0.036) (Table&#x000a0;<a href="#cts13828-supitem-0001" rid="cts13828-supitem-0001" class=" supplementary-material">S1</a>). Tauroursodeoxycholic acid (T&#x02010;UDCA) was also lower in those who developed CVAE compared with those who did not (fold change&#x02009;=&#x02009;0.28, <em>p</em>&#x02009;=&#x02009;0.0076, FDR adjusted <em>p</em>&#x02009;=&#x02009;0.197) (Table&#x000a0;<a href="#cts13828-supitem-0001" rid="cts13828-supitem-0001" class=" supplementary-material">S1</a>).</p><p>The only significant clinical variables associated with CVAE were the binary variables of whether or not BNP/NT&#x02010;ProBNP levels is above the cutoff (BNP&#x02009;&#x0003e;&#x02009;100&#x02009;pg/mL or NT&#x02010;proBNP &#x0003e;125&#x02009;pg/mL) or not and the medical history of hypertension. In the adjusted analysis, 29 baseline metabolites remained nominally significant after adjusting for BNP/NT&#x02010;proBNP above threshold and hypertension (Table&#x000a0;<a href="/pmc/articles/PMC11116757/table/cts13828-tbl-0002/" target="table" class="fig-table-link figpopup" rid-figpopup="cts13828-tbl-0002" rid-ob="ob-cts13828-tbl-0002" co-legend-rid=""><span>2</span></a>). These baseline metabolites with <em>p</em>&#x02009;&#x0003c;&#x02009;0.05 and odds ratio (OR)&#x02009;&#x02265;&#x02009;1.2 or &#x02264;0.83 are highlighted in a volcano plot Figure&#x000a0;<a href="/pmc/articles/PMC11116757/figure/cts13828-fig-0001/" target="figure" class="fig-table-link figpopup" rid-figpopup="cts13828-fig-0001" rid-ob="ob-cts13828-fig-0001" co-legend-rid="lgnd_cts13828-fig-0001"><span>1a</span></a>. The heat map based on the top known significant baseline metabolites is shown in Figure&#x000a0;<a href="/pmc/articles/PMC11116757/figure/cts13828-fig-0001/" target="figure" class="fig-table-link figpopup" rid-figpopup="cts13828-fig-0001" rid-ob="ob-cts13828-fig-0001" co-legend-rid="lgnd_cts13828-fig-0001"><span>1b</span></a>.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="cts13828-tbl-0002"><h3>TABLE 2</h3><!--caption a7--><div class="caption"><p>Baseline metabolites associated with carfilzomib&#x02010;CVAE in patients with MM.</p></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Metabolites</th><th align="left" valign="bottom" rowspan="1" colspan="1">HMDB ID or KEGG ID</th><th align="left" valign="bottom" rowspan="1" colspan="1">Polarity</th><th align="left" valign="bottom" rowspan="1" colspan="1">M/z</th><th align="left" valign="bottom" rowspan="1" colspan="1">RT (min)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Odds ratio</th><th align="left" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<em>p</em>
<sup>
a
</sup>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">N&#x02010;Acetyl aspartylglutamic acid</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0001067</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">303.0832</td><td align="center" valign="top" rowspan="1" colspan="1">2.97</td><td align="center" valign="top" rowspan="1" colspan="1">0.27</td><td align="center" valign="top" rowspan="1" colspan="1">0.11&#x02013;0.59</td><td align="center" valign="top" rowspan="1" colspan="1">0.0023</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P&#x02010;cresol</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0001858</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">107.0500</td><td align="center" valign="top" rowspan="1" colspan="1">9.47</td><td align="center" valign="top" rowspan="1" colspan="1">0.29</td><td align="center" valign="top" rowspan="1" colspan="1">0.11&#x02013;0.61</td><td align="center" valign="top" rowspan="1" colspan="1">0.0034</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">N&#x02010;palmitoyl taurine</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0240594</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="center" valign="top" rowspan="1" colspan="1">386.2374</td><td align="center" valign="top" rowspan="1" colspan="1">7.73</td><td align="center" valign="top" rowspan="1" colspan="1">0.31</td><td align="center" valign="top" rowspan="1" colspan="1">0.12&#x02013;0.65</td><td align="center" valign="top" rowspan="1" colspan="1">0.0050</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P&#x02010;hydroxyphenyl acetate,3&#x02010;hydroxy phenylacetate, Mandelic acid</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0000020; HMDB0000440; HMDB0062635</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">151.0398</td><td align="center" valign="top" rowspan="1" colspan="1">9.43</td><td align="center" valign="top" rowspan="1" colspan="1">0.35</td><td align="center" valign="top" rowspan="1" colspan="1">0.15&#x02013;0.71</td><td align="center" valign="top" rowspan="1" colspan="1">0.0070</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4&#x02010;Nitrophenyl diphenylphosphinate</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0246541</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">338.0584</td><td align="center" valign="top" rowspan="1" colspan="1">6.12</td><td align="center" valign="top" rowspan="1" colspan="1">0.33</td><td align="center" valign="top" rowspan="1" colspan="1">0.13&#x02013;0.70</td><td align="center" valign="top" rowspan="1" colspan="1">0.0083</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Phenylalanylaspartic</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0028991</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="center" valign="top" rowspan="1" colspan="1">281.1130</td><td align="center" valign="top" rowspan="1" colspan="1">8.53</td><td align="center" valign="top" rowspan="1" colspan="1">0.35</td><td align="center" valign="top" rowspan="1" colspan="1">0.15&#x02013;0.72</td><td align="center" valign="top" rowspan="1" colspan="1">0.0085</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Citramalate</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0000426</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">147.0297</td><td align="center" valign="top" rowspan="1" colspan="1">2.18</td><td align="center" valign="top" rowspan="1" colspan="1">0.33</td><td align="center" valign="top" rowspan="1" colspan="1">0.13&#x02013;0.70</td><td align="center" valign="top" rowspan="1" colspan="1">0.0086</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Glycocholic acid</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0000138; HMDB0240607</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">464.3013</td><td align="center" valign="top" rowspan="1" colspan="1">9.96</td><td align="center" valign="top" rowspan="1" colspan="1">0.33</td><td align="center" valign="top" rowspan="1" colspan="1">0.12&#x02013;0.72</td><td align="center" valign="top" rowspan="1" colspan="1">0.0116</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Citramalate</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0000426</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="center" valign="top" rowspan="1" colspan="1">171.0261</td><td align="center" valign="top" rowspan="1" colspan="1">2.21</td><td align="center" valign="top" rowspan="1" colspan="1">0.36</td><td align="center" valign="top" rowspan="1" colspan="1">0.15&#x02013;0.75</td><td align="center" valign="top" rowspan="1" colspan="1">0.0119</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4&#x02010;Hydroxyphenylacetic acid sulfate</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0304906</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">230.9964</td><td align="center" valign="top" rowspan="1" colspan="1">7.35</td><td align="center" valign="top" rowspan="1" colspan="1">0.29</td><td align="center" valign="top" rowspan="1" colspan="1">0.10&#x02013;0.70</td><td align="center" valign="top" rowspan="1" colspan="1">0.0120</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pimelic acid</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0000857</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">159.0659</td><td align="center" valign="top" rowspan="1" colspan="1">2.01</td><td align="center" valign="top" rowspan="1" colspan="1">2.47</td><td align="center" valign="top" rowspan="1" colspan="1">1.26&#x02013;5.41</td><td align="center" valign="top" rowspan="1" colspan="1">0.0136</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Taurochenodesoxycholic acid (T&#x02010;CDCA)</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0000951</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">498.2891</td><td align="center" valign="top" rowspan="1" colspan="1">10.57</td><td align="center" valign="top" rowspan="1" colspan="1">0.33</td><td align="center" valign="top" rowspan="1" colspan="1">0.12&#x02013;0.75</td><td align="center" valign="top" rowspan="1" colspan="1">0.0156</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Phenol</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0000228</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">93.0339</td><td align="center" valign="top" rowspan="1" colspan="1">9.47</td><td align="center" valign="top" rowspan="1" colspan="1">0.43</td><td align="center" valign="top" rowspan="1" colspan="1">0.20&#x02013;0.84</td><td align="center" valign="top" rowspan="1" colspan="1">0.0190</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Taurochenodesoxycholic acid (T&#x02010;CDCA)</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0000951</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="center" valign="top" rowspan="1" colspan="1">464.2819</td><td align="center" valign="top" rowspan="1" colspan="1">10.55</td><td align="center" valign="top" rowspan="1" colspan="1">0.38</td><td align="center" valign="top" rowspan="1" colspan="1">0.16&#x02013;0.81</td><td align="center" valign="top" rowspan="1" colspan="1">0.0200</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hexanoylglycine</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0000701</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">172.0979</td><td align="center" valign="top" rowspan="1" colspan="1">7.13</td><td align="center" valign="top" rowspan="1" colspan="1">2.52</td><td align="center" valign="top" rowspan="1" colspan="1">1.21&#x02013;6.16</td><td align="center" valign="top" rowspan="1" colspan="1">0.0235</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4&#x02010;methyl&#x02010;2&#x02010;oxo&#x02010;pentanoic acid</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0245963</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">175.0612</td><td align="center" valign="top" rowspan="1" colspan="1">7.32</td><td align="center" valign="top" rowspan="1" colspan="1">0.45</td><td align="center" valign="top" rowspan="1" colspan="1">0.20&#x02013;0.87</td><td align="center" valign="top" rowspan="1" colspan="1">0.0250</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dihydrophaseic_acid</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0038660</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">281.1399</td><td align="center" valign="top" rowspan="1" colspan="1">10.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.41</td><td align="center" valign="top" rowspan="1" colspan="1">0.17&#x02013;0.82</td><td align="center" valign="top" rowspan="1" colspan="1">0.0253</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Glycohyocholic acid</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0240607</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">191.0813</td><td align="center" valign="top" rowspan="1" colspan="1">7.12</td><td align="center" valign="top" rowspan="1" colspan="1">0.40</td><td align="center" valign="top" rowspan="1" colspan="1">0.16&#x02013;0.85</td><td align="center" valign="top" rowspan="1" colspan="1">0.0278</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2&#x02010;methylglutaric acid</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0000752</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">167.0323</td><td align="center" valign="top" rowspan="1" colspan="1">7.06</td><td align="center" valign="top" rowspan="1" colspan="1">0.43</td><td align="center" valign="top" rowspan="1" colspan="1">0.19&#x02013;0.88</td><td align="center" valign="top" rowspan="1" colspan="1">0.0295</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">6&#x02010;Hydroxy&#x02010;1H&#x02010;indole&#x02010;3&#x02010;acetamide</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0031645</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="center" valign="top" rowspan="1" colspan="1">191.0810</td><td align="center" valign="top" rowspan="1" colspan="1">7.12</td><td align="center" valign="top" rowspan="1" colspan="1">0.43</td><td align="center" valign="top" rowspan="1" colspan="1">0.19&#x02013;0.88</td><td align="center" valign="top" rowspan="1" colspan="1">0.0296</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Glycine&#x02010;glutamine</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0028840</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">203.0670</td><td align="center" valign="top" rowspan="1" colspan="1">0.9</td><td align="center" valign="top" rowspan="1" colspan="1">2.34</td><td align="center" valign="top" rowspan="1" colspan="1">1.12&#x02013;5.32</td><td align="center" valign="top" rowspan="1" colspan="1">0.0298</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">N&#x02010;acetylcadaverine</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0002284</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="center" valign="top" rowspan="1" colspan="1">145.1333</td><td align="center" valign="top" rowspan="1" colspan="1">1.85</td><td align="center" valign="top" rowspan="1" colspan="1">2.95</td><td align="center" valign="top" rowspan="1" colspan="1">0.19&#x02013;0.88</td><td align="center" valign="top" rowspan="1" colspan="1">0.0303</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tauro&#x02010;muricholic acid</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0000932</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">514.2836</td><td align="center" valign="top" rowspan="1" colspan="1">9.41</td><td align="center" valign="top" rowspan="1" colspan="1">0.45</td><td align="center" valign="top" rowspan="1" colspan="1">1.25&#x02013;9.06</td><td align="center" valign="top" rowspan="1" colspan="1">0.0335</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">C12h22o11&#x02010;disaccharide&#x02010;(6c/6c; glc&#x02010;glc/glc&#x02010;frc/gal&#x02010;glc)</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0000163</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">341.1091</td><td align="center" valign="top" rowspan="1" colspan="1">0.87</td><td align="center" valign="top" rowspan="1" colspan="1">0.49</td><td align="center" valign="top" rowspan="1" colspan="1">0.20&#x02013;0.90</td><td align="center" valign="top" rowspan="1" colspan="1">0.0391</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5&#x02010;Carboxymethyl&#x02010;2&#x02010;hydroxymuconate</td><td align="left" valign="top" rowspan="1" colspan="1"><a id="__tag_1149237048" class="tag_hotlink" href="/nuccore/C04186" ref="/nuccore/C04186"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"C04186","term_id":"1467437","term_text":"C04186"}}</span>C04186</a></td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">215.0185</td><td align="center" valign="top" rowspan="1" colspan="1">9.78</td><td align="center" valign="top" rowspan="1" colspan="1">0.42</td><td align="center" valign="top" rowspan="1" colspan="1">0.23&#x02013;0.93</td><td align="center" valign="top" rowspan="1" colspan="1">0.0431</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Enkephali&#x02010;L</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0001045</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">578.2636</td><td align="center" valign="top" rowspan="1" colspan="1">10.78</td><td align="center" valign="top" rowspan="1" colspan="1">0.46</td><td align="center" valign="top" rowspan="1" colspan="1">0.17&#x02013;0.89</td><td align="center" valign="top" rowspan="1" colspan="1">0.0432</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tauroursodeoxycholic acid (T&#x02010;UDCA)</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0000874</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">498.2891</td><td align="center" valign="top" rowspan="1" colspan="1">10.02</td><td align="center" valign="top" rowspan="1" colspan="1">0.47</td><td align="center" valign="top" rowspan="1" colspan="1">0.20&#x02013;0.93</td><td align="center" valign="top" rowspan="1" colspan="1">0.0440</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Homovanillate</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0011719</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">181.0505</td><td align="center" valign="top" rowspan="1" colspan="1">7.71</td><td align="center" valign="top" rowspan="1" colspan="1">2.40</td><td align="center" valign="top" rowspan="1" colspan="1">0.21&#x02013;0.94</td><td align="center" valign="top" rowspan="1" colspan="1">0.0470</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Homocysteine</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0000742</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="center" valign="top" rowspan="1" colspan="1">136.0424</td><td align="center" valign="top" rowspan="1" colspan="1">1.3</td><td align="center" valign="top" rowspan="1" colspan="1">2.18</td><td align="center" valign="top" rowspan="1" colspan="1">1.08&#x02013;6.32</td><td align="center" valign="top" rowspan="1" colspan="1">0.0482</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lys&#x02010;trp&#x02010;oh</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0028962</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">439.1610</td><td align="center" valign="top" rowspan="1" colspan="1">9.53</td><td align="center" valign="top" rowspan="1" colspan="1">0.41</td><td align="center" valign="top" rowspan="1" colspan="1">1.08&#x02013;5.12</td><td align="center" valign="top" rowspan="1" colspan="1">0.0493</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm140308753123168"><a target="object" rel="noopener" href="/pmc/articles/PMC11116757/table/cts13828-tbl-0002/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="cts13828-note-0005"><p class="p p-first-last">Abbreviations: CVAE, cardiovascular adverse events; CI, confidence interval; MM, multiple myeloma; RT, retention time.</p></div><div id="cts13828-note-0006"><sup>
a
</sup>All <em>p</em>&#x02010;values were adjusted for BNP/NT&#x02010;proBNP above threshold (BNP&#x02009;&#x0003e;100&#x02009;pg/mL or NT&#x02010;proBNP &#x0003e;125&#x02009;pg/mL) and hypertension.</div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="cts13828-fig-0001" co-legend-rid="lgnd_cts13828-fig-0001"><a href="/pmc/articles/PMC11116757/figure/cts13828-fig-0001/" target="figure" rid-figpopup="cts13828-fig-0001" rid-ob="ob-cts13828-fig-0001"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140308749208544"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is CTS-17-e13828-g002.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is CTS-17-e13828-g002.jpg" src="/pmc/articles/PMC11116757/bin/CTS-17-e13828-g002.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm140308749208544"><a target="object" rel="noopener" href="/pmc/articles/PMC11116757/figure/cts13828-fig-0001/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_cts13828-fig-0001"><div><a class="figpopup" href="/pmc/articles/PMC11116757/figure/cts13828-fig-0001/" target="figure" rid-figpopup="cts13828-fig-0001" rid-ob="ob-cts13828-fig-0001">FIGURE 1</a></div><!--caption a7--><div class="caption"><p>Top baseline metabolites associated with carfilzomib&#x02010;CVAE. (a) Volcano plot for baseline metabolites. Baseline metabolites with <em>p</em>&#x02009;&#x0003c;&#x02009;0.05 are shown in red (if odds ratios &#x02265;1.2) or blue (if odds ratios &#x02264;0.83). (b) Heatmap of top baseline metabolites. Top baseline metabolites with <em>p</em>&#x02009;&#x0003c;&#x02009;0.05 and odds ratios &#x02265;1.2 and&#x02009;&#x02264;0.83 are shown.</p></div></div></div><p class="p p-last">Among the top baseline metabolites associated with lower odds of CVAE in the adjusted analyses were N&#x02010;acetyl aspartyl glutamic acid (OR&#x02009;=&#x02009;0.27, 95% CI&#x02009;=&#x02009;0.11&#x02013;0.59, <em>p</em>&#x02009;=&#x02009;0.0023), GCA (OR&#x02009;=&#x02009;0.33, 95% CI&#x02009;=&#x02009;0.12&#x02013;0.72, <em>p</em>&#x02009;=&#x02009;0.012), T&#x02010;UDCA (OR&#x02009;=&#x02009;0.47, 95% CI&#x02009;=&#x02009;0.02&#x02013;0.94, <em>p</em>&#x02009;=&#x02009;0.044; Table&#x000a0;<a href="/pmc/articles/PMC11116757/table/cts13828-tbl-0002/" target="table" class="fig-table-link figpopup" rid-figpopup="cts13828-tbl-0002" rid-ob="ob-cts13828-tbl-0002" co-legend-rid=""><span>2</span></a>). A higher level of acetylcadaverine was associated with higher odds of CVAE (OR&#x02009;=&#x02009;2.95, 95% CI&#x02009;=&#x02009;1.25&#x02013;9.06, <em>p</em>&#x02009;=&#x02009;0.030; Table&#x000a0;<a href="/pmc/articles/PMC11116757/table/cts13828-tbl-0002/" target="table" class="fig-table-link figpopup" rid-figpopup="cts13828-tbl-0002" rid-ob="ob-cts13828-tbl-0002" co-legend-rid=""><span>2</span></a>).</p></div><div id="cts13828-sec-0014" class="sec"><h3 id="cts13828-sec-0014title">Predictive model with baseline metabolites</h3><p class="p p-first">To develop a predictive model for CVAE using baseline metabolites, we included all the top metabolites with <em>p</em>&#x02009;&#x0003c;&#x02009;0.05 from univariate analysis in a LASSO Cox regression model along with the clinical variables. In the LASSO Cox regression analysis, five baseline metabolites (T&#x02010;UDCA, Gly&#x02010;Glu, p&#x02010;Cresol, acetylcadaverine, and 4&#x02010;nitrophenyl diphenylphosphinate) were selected as important predictors for CVAE in addition to the binary variable of baseline BNP/NT&#x02010;proBNP higher than cutoff values (BNP&#x02009;&#x0003e;&#x02009;100&#x02009;pg/mL or NT&#x02010;proBNP &#x0003e;125&#x02009;pg/mL) (Table&#x000a0;<a href="#cts13828-supitem-0001" rid="cts13828-supitem-0001" class=" supplementary-material">S2</a>). A metabolomic risk score was created to combine these metabolites into one MRS weighted by the beta&#x02010;coefficients.</p><p class="p">We used the tertile of the MRS to stratify patients into three risk groups: low&#x02010;, intermediate&#x02010;, and high&#x02010;risk groups, with CVAE event rates of 21.05%, 36.84%, and 89.47%, respectively (Figure&#x000a0;<a href="/pmc/articles/PMC11116757/figure/cts13828-fig-0002/" target="figure" class="fig-table-link figpopup" rid-figpopup="cts13828-fig-0002" rid-ob="ob-cts13828-fig-0002" co-legend-rid="lgnd_cts13828-fig-0002"><span>2a</span></a>). The Kaplan&#x02013;Meier curve for the time to CVAE by these three groups is shown in Figure&#x000a0;<a href="/pmc/articles/PMC11116757/figure/cts13828-fig-0002/" target="figure" class="fig-table-link figpopup" rid-figpopup="cts13828-fig-0002" rid-ob="ob-cts13828-fig-0002" co-legend-rid="lgnd_cts13828-fig-0002"><span>2b</span></a>. We have created three different models: Model 1. History of Hypertension; Model 2. Hypertension + BNP; Model 3: Hypertension + BNP&#x02009;+&#x02009;MRS. The ROC curves of these models are shown in Figure&#x000a0;<a href="/pmc/articles/PMC11116757/figure/cts13828-fig-0002/" target="figure" class="fig-table-link figpopup" rid-figpopup="cts13828-fig-0002" rid-ob="ob-cts13828-fig-0002" co-legend-rid="lgnd_cts13828-fig-0002"><span>2c</span></a>. The area under ROC curve (AUC) was 0.63 for the model with hypertension alone, and 0.78 for hypertension + BNP, and 0.93 with hypertension + BNP&#x02009;+&#x02009;MRS. The <em>p</em>&#x02010;values were 0.02004 comparing Model 1 and Model 2, and <em>p</em>&#x02009;=&#x02009;0.000003 for increase in AUC from Model 1 to Model 3 based on Delong's statistic for comparing the AUCs.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="cts13828-fig-0002" co-legend-rid="lgnd_cts13828-fig-0002"><a href="/pmc/articles/PMC11116757/figure/cts13828-fig-0002/" target="figure" rid-figpopup="cts13828-fig-0002" rid-ob="ob-cts13828-fig-0002"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140308749190656"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is CTS-17-e13828-g001.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is CTS-17-e13828-g001.jpg" src="/pmc/articles/PMC11116757/bin/CTS-17-e13828-g001.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm140308749190656"><a target="object" rel="noopener" href="/pmc/articles/PMC11116757/figure/cts13828-fig-0002/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_cts13828-fig-0002"><div><a class="figpopup" href="/pmc/articles/PMC11116757/figure/cts13828-fig-0002/" target="figure" rid-figpopup="cts13828-fig-0002" rid-ob="ob-cts13828-fig-0002">FIGURE 2</a></div><!--caption a7--><div class="caption"><p>Carfilzomib&#x02010;CVAE by metabolite risk score. (a) Event rate by MRS tertile; (b) Kaplan&#x02013;Meier curve of time&#x02010;to&#x02010;CVAE by MRS tertile; (c) Receiver&#x02010;operating curves for three models: hypertension (HTN) alone; HTN&#x02009;+&#x02009;BNP/NT&#x02010;proBNP above threshold (BNPCUT); HTN&#x02009;+&#x02009;BNP/NT&#x02010;proBNP above threshold (BNPCUT) + MRS. The area under the ROC curves were 0.63, 0.78, and 0.93, respectively.</p></div></div></div></div><div id="cts13828-sec-0015" class="sec"><h3 id="cts13828-sec-0015title">Metabolite change after carfilzomib treatment</h3><p class="p p-first">To identify the metabolites that changed significantly as a result of carfilzomib treatment, the post&#x02010;baseline/baseline ratios of each metabolite were compared between the patients with and without CVAE. In the unadjusted analysis, the post&#x02010;baseline/baseline ratio of 12 known metabolites had <em>p</em>&#x02010;values &#x0003c;0.05 and fold change &#x02265;1.5 or &#x02264;0.67 between the two groups of patients (Table&#x000a0;<a href="#cts13828-supitem-0001" rid="cts13828-supitem-0001" class=" supplementary-material">S3</a>). The top metabolite was glycochenodeoxycholic acid (GCDCA), with a fold change of 0.42 (<em>p</em>&#x02009;=&#x02009;0.02) (Table&#x000a0;<a href="#cts13828-supitem-0001" rid="cts13828-supitem-0001" class=" supplementary-material">S3</a>). After adjusting for the history of hypertension and BNP/NT&#x02010;proBNP levels above the cutoff, the post&#x02010;baseline/baseline ratios of nine metabolites were significantly associated with CVAE (Table&#x000a0;<a href="/pmc/articles/PMC11116757/table/cts13828-tbl-0003/" target="table" class="fig-table-link figpopup" rid-figpopup="cts13828-tbl-0003" rid-ob="ob-cts13828-tbl-0003" co-legend-rid=""><span>3</span></a>). The volcano plot and heat map of the top known metabolites for post&#x02010;baseline/baseline are shown in Figure&#x000a0;<a href="/pmc/articles/PMC11116757/figure/cts13828-fig-0003/" target="figure" class="fig-table-link figpopup" rid-figpopup="cts13828-fig-0003" rid-ob="ob-cts13828-fig-0003" co-legend-rid="lgnd_cts13828-fig-0003"><span>3a,b</span></a>, respectively. The top post&#x02010;baseline/baseline metabolite ratios that were different between the CVAE vs no&#x02010;CVAE patients included 2,3&#x02010;dihydroxybenzoate (OR&#x02009;=&#x02009;0.63, 95% CI&#x02009;=&#x02009;0.44&#x02013;0.88, <em>p</em>&#x02009;=&#x02009;0.022), GCDCA (OR&#x02009;=&#x02009;0.56, 95% CI&#x02009;=&#x02009;0.31&#x02013;0.87, <em>p</em>&#x02009;=&#x02009;0.023), ferulic acid sulfate (OR&#x02009;=&#x02009;0.84, 95% CI&#x02009;=&#x02009;0.7&#x02013;0.96, <em>p</em>&#x02009;=&#x02009;0.029), and glycodeoxycholic acid (GDCA) (OR&#x02009;=&#x02009;0.72, 95% CI&#x02009;=&#x02009;0.50&#x02013;0.93, <em>p</em>&#x02009;=&#x02009;0.034). However, the post&#x02010;baseline/baseline ratio of T&#x02010;UDCA were not significantly different between CVAE and no&#x02010;CVAE patients (OR&#x02009;=&#x02009;0.98, 95% CI&#x02009;=&#x02009;0.85&#x02013;1.07, <em>p</em>&#x02009;=&#x02009;0.73).</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="cts13828-tbl-0003"><h3>TABLE 3</h3><!--caption a7--><div class="caption"><p>Post&#x02010;baseline/baseline metabolites that differed in MM patients with or without carfilzomib&#x02010;CVAE.</p></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Metabolites</th><th align="left" valign="bottom" rowspan="1" colspan="1">HMDB ID or KEGG ID</th><th align="left" valign="bottom" rowspan="1" colspan="1">Polarity</th><th align="left" valign="bottom" rowspan="1" colspan="1">m/z</th><th align="left" valign="bottom" rowspan="1" colspan="1">RT</th><th align="left" valign="bottom" rowspan="1" colspan="1">Odds ratio</th><th align="left" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<em>p</em>
<sup>
a
</sup>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">2,3&#x02010;Dihydroxybenzoate</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0029666</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">153.019</td><td align="center" valign="top" rowspan="1" colspan="1">8.60</td><td align="center" valign="top" rowspan="1" colspan="1">0.63</td><td align="center" valign="top" rowspan="1" colspan="1">0.40&#x02013;0.90</td><td align="center" valign="top" rowspan="1" colspan="1">0.022</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Glycochenodeoxycholic acid (GCDCA)</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0000637</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="center" valign="top" rowspan="1" colspan="1">450.3207</td><td align="center" valign="top" rowspan="1" colspan="1">11.52</td><td align="center" valign="top" rowspan="1" colspan="1">0.56</td><td align="center" valign="top" rowspan="1" colspan="1">0.31&#x02013;0.87</td><td align="center" valign="top" rowspan="1" colspan="1">0.023</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ferulic acid sulfate</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0029200</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">273.0070</td><td align="center" valign="top" rowspan="1" colspan="1">8.39</td><td align="center" valign="top" rowspan="1" colspan="1">0.83</td><td align="center" valign="top" rowspan="1" colspan="1">0.70&#x02013;0.96</td><td align="center" valign="top" rowspan="1" colspan="1">0.029</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hexanoylglycine</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0000701</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">172.0979</td><td align="center" valign="top" rowspan="1" colspan="1">7.33</td><td align="center" valign="top" rowspan="1" colspan="1">1.58</td><td align="center" valign="top" rowspan="1" colspan="1">1.10&#x02013;2.65</td><td align="center" valign="top" rowspan="1" colspan="1">0.033</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">N&#x02010;acetyl&#x02010;l&#x02010;alanine</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0000766</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="center" valign="top" rowspan="1" colspan="1">114.0550&#x02010;</td><td align="center" valign="top" rowspan="1" colspan="1">2.23</td><td align="center" valign="top" rowspan="1" colspan="1">0.80</td><td align="center" valign="top" rowspan="1" colspan="1">0.62&#x02013;0.95</td><td align="center" valign="top" rowspan="1" colspan="1">0.033</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2&#x02010;acetamido&#x02010;2&#x02010;deoxy&#x02010;beta&#x02010;d&#x02010;glucosylamine</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0030091</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="center" valign="top" rowspan="1" colspan="1">203.1025</td><td align="center" valign="top" rowspan="1" colspan="1">0.90</td><td align="center" valign="top" rowspan="1" colspan="1">1.35</td><td align="center" valign="top" rowspan="1" colspan="1">1.07&#x02013;1.92</td><td align="center" valign="top" rowspan="1" colspan="1">0.033</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Glycodeoxycholic acid (GDCA)</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0341325</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="center" valign="top" rowspan="1" colspan="1">414.2993</td><td align="center" valign="top" rowspan="1" colspan="1">11.52</td><td align="center" valign="top" rowspan="1" colspan="1">0.72</td><td align="center" valign="top" rowspan="1" colspan="1">0.50&#x02013;0.93</td><td align="center" valign="top" rowspan="1" colspan="1">0.034</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Inosine</td><td align="left" valign="top" rowspan="1" colspan="1">HMDB0000189</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="center" valign="top" rowspan="1" colspan="1">291.0694</td><td align="center" valign="top" rowspan="1" colspan="1">6.01</td><td align="center" valign="top" rowspan="1" colspan="1">1.31</td><td align="center" valign="top" rowspan="1" colspan="1">1.05&#x02013;1.77</td><td align="center" valign="top" rowspan="1" colspan="1">0.035</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Aldopentose</td><td align="left" valign="top" rowspan="1" colspan="1"><a id="__tag_1149237047" class="tag_hotlink" href="/nuccore/C00117" ref="/nuccore/C00117"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"C00117","term_id":"1432347","term_text":"C00117"}}</span>C00117</a></td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="center" valign="top" rowspan="1" colspan="1">173.0418</td><td align="center" valign="top" rowspan="1" colspan="1">0.85</td><td align="center" valign="top" rowspan="1" colspan="1">1.23</td><td align="center" valign="top" rowspan="1" colspan="1">1.04&#x02013;1.56</td><td align="center" valign="top" rowspan="1" colspan="1">0.038</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm140308749176064"><a target="object" rel="noopener" href="/pmc/articles/PMC11116757/table/cts13828-tbl-0003/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="cts13828-note-0007"><p class="p p-first-last">Abbreviations: CI, confidence intervals; CVAE, cardiovascular adverse events; MM, multiple myeloma; RT, Retention time.</p></div><div id="cts13828-note-0008"><sup>
a
</sup>All <em>p</em>&#x02010;values were adjusted for BNP/NT&#x02010;proBNP above threshold (BNP&#x02009;&#x0003e;100&#x02009;pg/mL or NT&#x02010;proBNP &#x0003e;125&#x02009;pg/mL) and hypertension.</div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="cts13828-fig-0003" co-legend-rid="lgnd_cts13828-fig-0003"><a href="/pmc/articles/PMC11116757/figure/cts13828-fig-0003/" target="figure" rid-figpopup="cts13828-fig-0003" rid-ob="ob-cts13828-fig-0003"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140308749045280"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is CTS-17-e13828-g003.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is CTS-17-e13828-g003.jpg" src="/pmc/articles/PMC11116757/bin/CTS-17-e13828-g003.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm140308749045280"><a target="object" rel="noopener" href="/pmc/articles/PMC11116757/figure/cts13828-fig-0003/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_cts13828-fig-0003"><div><a class="figpopup" href="/pmc/articles/PMC11116757/figure/cts13828-fig-0003/" target="figure" rid-figpopup="cts13828-fig-0003" rid-ob="ob-cts13828-fig-0003">FIGURE 3</a></div><!--caption a7--><div class="caption"><p>Top metabolite changes after carfilzomib treatment. (a) Volcano plot for post&#x02010;baseline/baseline metabolite ratios. Post&#x02010;baseline/baseline metabolites with <em>p</em>&#x02009;&#x0003c;&#x02009;0.05 are shown in red (if odds ratio&#x02009;&#x0003e;1.2) or blue (if odds ratio&#x02009;&#x0003c;0.83). (b) Heatmap for the metabolites with post&#x02010;baseline/baseline ratios <em>p</em>&#x02009;&#x0003c;&#x02009;0.05 and odds ratios &#x02265;1.2 and&#x02009;&#x02264;0.83 are shown.</p></div></div></div></div><div id="cts13828-sec-0016" class="sec sec-last"><h3 id="cts13828-sec-0016title">Pathway analysis</h3><p class="p p-first">The Human Metabolome Database IDs of metabolites with significance were uploaded to IPA and pathway analyses were performed. Bile acid biosynthesis, bile acid and bile salt metabolism, cysteine biosynthesis/homocysteine degradation, etc. pathways were found to be the most significant pathways enriched with the top baseline metabolites for carfilzomib&#x02010;CVAE (Table&#x000a0;<a href="/pmc/articles/PMC11116757/table/cts13828-tbl-0004/" target="table" class="fig-table-link figpopup" rid-figpopup="cts13828-tbl-0004" rid-ob="ob-cts13828-tbl-0004" co-legend-rid=""><span>4</span></a>). The ratio of post&#x02010;baseline/baseline metabolites that differed between CVAE and no&#x02010;CVAE patients were enriched in pathways, such as bile acid biosynthesis, bile acid, and bile salt metabolism (Table&#x000a0;<a href="/pmc/articles/PMC11116757/table/cts13828-tbl-0004/" target="table" class="fig-table-link figpopup" rid-figpopup="cts13828-tbl-0004" rid-ob="ob-cts13828-tbl-0004" co-legend-rid=""><span>4</span></a>).</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="cts13828-tbl-0004"><h3>TABLE 4</h3><!--caption a7--><div class="caption"><p>Top canonical pathways associated with the top metabolites in Ingenuity pathway analyses.</p></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Top pathway</th><th align="left" valign="bottom" rowspan="1" colspan="1">Affiliated metabolites</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<em>p</em>
</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="3" valign="top" rowspan="1">
<em>Baseline metabolites</em>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bile acid biosynthesis, neutral pathway</td><td align="left" valign="top" rowspan="1" colspan="1">Glycocholic acid, taurochenodeoxycholate, tauroursodeoxycholic acid</td><td align="left" valign="top" rowspan="1" colspan="1">1.49 &#x000d7;&#x02009;10<sup>&#x02212;2</sup>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bile acid and bile salt metabolism</td><td align="left" valign="top" rowspan="1" colspan="1">Glycocholic acid, taurochenodeoxycholate, tauroursodeoxycholic acid</td><td align="left" valign="top" rowspan="1" colspan="1">2.01 &#x000d7;&#x02009;10<sup>&#x02212;2</sup>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Methionine salvage II (Mammalian)</td><td align="left" valign="top" rowspan="1" colspan="1">L&#x02010;homocysteine</td><td align="left" valign="top" rowspan="1" colspan="1">2.79 &#x000d7;&#x02009;10<sup>&#x02212;2</sup>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cysteine biosynthesis/homocysteine degradation</td><td align="left" valign="top" rowspan="1" colspan="1">L&#x02010;homocysteine</td><td align="left" valign="top" rowspan="1" colspan="1">2.79 &#x000d7;&#x02009;10<sup>&#x02212;2</sup>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Methionine degradation I (to homocysteine)</td><td align="left" valign="top" rowspan="1" colspan="1">L&#x02010;homocysteine</td><td align="left" valign="top" rowspan="1" colspan="1">3.70 &#x000d7;&#x02009;10<sup>&#x02212;2</sup>
</td></tr><tr><td align="left" colspan="3" valign="top" rowspan="1">
<em>Post&#x02010;baseline/baseline metabolites</em>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bile acid biosynthesis, neutral pathway</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Glycochenodeoxycholic acid</p>
<p>Glycodeoxycholic acid (GDCA)</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">2.15 &#x000d7;&#x02009;10<sup>&#x02212;3</sup>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bile acid and bile salt metabolism</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Glycochenodeoxycholic acid</p>
<p>Glycodeoxycholic acid (GDCA)</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">2.98 &#x000d7;&#x02009;10<sup>&#x02212;3</sup>
</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm140308754712960"><a target="object" rel="noopener" href="/pmc/articles/PMC11116757/table/cts13828-tbl-0004/?report=objectonly">Open in a separate window</a></div></div></div></div><div id="cts13828-sec-0017" class="tsec sec"><h2 class="head no_bottom_margin" id="cts13828-sec-0017title">DISCUSSION</h2><p class="p p-first">In this global metabolomics study of MM patients treated with carfilzomib, we found lower levels of several bile acids such as T&#x02010;UDCA and GCA in the baseline plasma of patients who later developed CVAE compared with those who did not develop CVAE. We created an MRS based on a few baseline metabolites selected using the LASSO regression model. The performance of the model that included hypertension, BNP/NT&#x02010;proBNP above normal, and the MRS outperformed the model with hypertension alone and the model with hypertension and BNP. We also identified a few metabolites including GCDCA that changed differently between the CVAE and no&#x02010;CVAE patients after carfilzomib treatment.</p><p>Our study found that there was a lower baseline level of bile acid T&#x02010;UDCA in the patients who later developed CVAE compared with those who did not and that there were no differences in the changes in T&#x02010;UDCA after carfilzomib treatment between these two groups of patients. This suggests that this metabolite identified a high&#x02010;risk patient population prior to carfilzomib treatment. In combination with a few other baseline metabolites, clinical risk of hypertension, and high BNP/NT&#x02010;proBNP level, our model was able to stratify MM patients into different risk groups for carfilzomib&#x02010;CVAE at baseline. If validated, this model could be used clinically to improve the baseline risk stratification of MM patients prior to carfilzomib treatment.</p><p>A mouse study by Efentakis et&#x000a0;al. demonstrated that the treatment with carfilzomib resulted in the repression of AMPK&#x003b1; phosphorylation as well as the PI3K/Akt/eNOS axis, which is responsible for myocardial cell growth and survival. Carfilzomib&#x02010;CVAE in this mouse study appeared to be mediated through AMPK&#x003b1; inactivation and reduction of autophagy&#x02010;related proteins.<sup><a href="#cts13828-bib-0022" rid="cts13828-bib-0022" class=" bibr popnode">
22
</a></sup> Another study supported that T&#x02010;UDCA may protect from cardiomyocyte contractility anomalies by restoration of mitochondrial damage through activation of AMPK&#x003b1; and Akt.<sup><a href="#cts13828-bib-0023" rid="cts13828-bib-0023" class=" bibr popnode">
23
</a></sup> Interestingly, studies on anthracycline doxorubicin illustrated the role of AMPK signaling in doxorubicin&#x02010;induced cardiotoxicity. The administration of doxorubicin blocks the AMPK pathway, resulting in a decrease in the activity of the ACC (Acetyl&#x02010;coA carboxylase) enzyme in the heart. Inhibition of AMPK signaling induced by doxorubicin leads to the activation of alternative pathways, including Akt and MAP kinase, triggered by genotoxic and oxidative stress, ultimately causing DNA damage. Additionally, the suppression of AMPK contributes to increased energetic stress and hypertrophy in cardiac tissue.<sup><a href="#cts13828-bib-0024" rid="cts13828-bib-0024" class=" bibr popnode">
24
</a></sup><sup>, </sup><sup><a href="#cts13828-bib-0025" rid="cts13828-bib-0025" class=" bibr popnode">
25
</a></sup>
</p><p>Bile acids have long been recognized as key regulators in the metabolic network and are involved in lipid metabolisms.<sup><a href="#cts13828-bib-0026" rid="cts13828-bib-0026" class=" bibr popnode">
26
</a></sup><sup>, </sup><sup><a href="#cts13828-bib-0027" rid="cts13828-bib-0027" class=" bibr popnode">
27
</a></sup><sup>, </sup><sup><a href="#cts13828-bib-0028" rid="cts13828-bib-0028" class=" bibr popnode">
28
</a></sup> Studies have associated abnormal bile acid metabolism disturbances with cardiac dysfunctions.<sup><a href="#cts13828-bib-0026" rid="cts13828-bib-0026" class=" bibr popnode">
26
</a></sup><sup>, </sup><sup><a href="#cts13828-bib-0029" rid="cts13828-bib-0029" class=" bibr popnode">
29
</a></sup> T&#x02010;UDCA is a hydrophilic bile acid and is known to inhibit endoplasmic reticulum (ER) stress.<sup><a href="#cts13828-bib-0030" rid="cts13828-bib-0030" class=" bibr popnode">
30
</a></sup> ER stress stimuli such as oxidative stress, ischemic insult, and altered calcium homeostasis can lead to cardiomyocyte apoptosis to HF.<sup><a href="#cts13828-bib-0031" rid="cts13828-bib-0031" class=" bibr popnode">
31
</a></sup><sup>, </sup><sup><a href="#cts13828-bib-0032" rid="cts13828-bib-0032" class=" bibr popnode">
32
</a></sup><sup>, </sup><sup><a href="#cts13828-bib-0033" rid="cts13828-bib-0033" class=" bibr popnode">
33
</a></sup> Several mouse studies have demonstrated that neuroprotective bile acid T&#x02010;UDCA mitigates cardiomyocyte contractility and overload&#x02010;induced hypertrophy by alleviation of ER stress markers<sup><a href="#cts13828-bib-0030" rid="cts13828-bib-0030" class=" bibr popnode">
30
</a></sup><sup>, </sup><sup><a href="#cts13828-bib-0034" rid="cts13828-bib-0034" class=" bibr popnode">
34
</a></sup><sup>, </sup><sup><a href="#cts13828-bib-0035" rid="cts13828-bib-0035" class=" bibr popnode">
35
</a></sup> and can ameliorate CVAE.<sup><a href="#cts13828-bib-0023" rid="cts13828-bib-0023" class=" bibr popnode">
23
</a></sup> A recent study on 48 patients with relapsed/refractory MM taking carfilzomib evaluated endothelial function using brachial artery flow&#x02010;mediated dilatation (FMD) and 26S proteasome activity (PrA) measurement. Both low baseline and reduced FMD after the first cycle were independently associated with CVAE, suggesting that this can be used as a biomarker for carfilzomib&#x02010;&#x02010;CVAE.<sup><a href="#cts13828-bib-0036" rid="cts13828-bib-0036" class=" bibr popnode">
36
</a></sup> The decreased level of FMD and PrA in the study indicated that carfilzomib treatment is related to endothelial dysfunction,<sup><a href="#cts13828-bib-0037" rid="cts13828-bib-0037" class=" bibr popnode">
37
</a></sup> which might lead to CVAE.<sup><a href="#cts13828-bib-0036" rid="cts13828-bib-0036" class=" bibr popnode">
36
</a></sup> Another study on mice showed that hypertension and ER stress can contribute to a great extent to vascular endothelial dysfunction. However, when they pretreated the endothelial cells with ER stress inhibitor T&#x02010;UDCA, the ER stress markers were found to be attenuated, indicating the role of T&#x02010;UDCA in the inhibition of coronary artery stimulation.<sup><a href="#cts13828-bib-0038" rid="cts13828-bib-0038" class=" bibr popnode">
38
</a></sup> In light of the literature, our finding appears to suggest that MM patients who went ahead to develop CVAE had endothelial dysfunction (lower level of protective biomarker T&#x02010;UDCA) prior to carfilzomib treatment. If validated, it may be plausible to consider using existing drugs such as T&#x02010;UDCA, statins (which enhance endothelial function) as cardioprotective agents for carfilzomib&#x02010;CVAE. Exercise may also be a reasonable cardioprotective strategy due to its benefit in improving endothelial function and cardiac function.<sup><a href="#cts13828-bib-0039" rid="cts13828-bib-0039" class=" bibr popnode">
39
</a></sup>
</p><p>We also evaluated the post&#x02010;baseline/baseline ratios of metabolites to investigate the effect of carfilzomib treatment. Our result showed that dihydroxybenzoate, GCDCA, and ferulic acid were the top metabolites that were significantly different between the CVAE and no&#x02010;CVAE patients. A study on dihydroxybenzoate showed that it induces the activation of a widely documented cardioprotective pathway in cardiomyocytes. This compound initiates the intracellular signaling cascade linked to preconditioning, which encompasses the generation of nitric oxide (NO) and cyclic guanosine monophosphate (cGMP), the stimulation of protein kinase G (PKG), the opening of mitochondrial ATP&#x02010;sensitive potassium (mitoKATP) channels, and the generation of reactive oxygen species (ROS). So dihydroxybenzoate safeguards the myocardium by stimulating nitric oxide synthase (NOS) and restricting the production of ROS within the mitochondria.<sup><a href="#cts13828-bib-0040" rid="cts13828-bib-0040" class=" bibr popnode">
40
</a></sup> Ferulic acid is available from some common food sources like coffee, whole grain oats flakes, popcorn, etc. Our study found a lower level of it in the patients with CVAE. The cardioprotective effectiveness of ferulic acid against doxorubicin&#x02010;induced cardiotoxicity was observed in a rat study by conducting its modification of oxidative stress, inflammation, ER stress, and calcium homeostasis. The ferulic acid treatment decreased the expression of BNP and enhanced the myocardial glutathione system and Na+/K+ ATPase. Ferulic acid might be exhibiting a cardioprotective effect by the activation of eNOS.<sup><a href="#cts13828-bib-0041" rid="cts13828-bib-0041" class=" bibr popnode">
41
</a></sup> Another study on mice demonstrated the efficacy of ferulic acid in mitigating cardiotoxicity induced by cyclophosphamide through the inhibition of the IKK/I&#x003ba;B/NF&#x02010;&#x003ba;B pathway and the subsequent reduction of inflammation. Ferulic acid possibly ameliorated the cardiotoxicity&#x02010;challenged heart through the IKK/I&#x003ba;B/NF&#x02010;&#x003ba;B signaling pathway.<sup><a href="#cts13828-bib-0042" rid="cts13828-bib-0042" class=" bibr popnode">
42
</a></sup> The EGFR/PI3K/Akt/mTORC1 pathway is found to regulate the IKK/NF&#x02010;&#x003ba;B signaling pathway.<sup><a href="#cts13828-bib-0043" rid="cts13828-bib-0043" class=" bibr popnode">
43
</a></sup> Our study also identified the glycoconjugate of chenodeoxycholic acid to have different post&#x02010;baseline/baseline ratios between CVAE and no&#x02010;CVAE patients. A study suggests that chenodeoxycholic acid enhances lipoprotein clearance to safeguard against atherosclerosis and improves cardiac function and remodeling after a myocardial infarction (MI).<sup><a href="#cts13828-bib-0044" rid="cts13828-bib-0044" class=" bibr popnode">
44
</a></sup>
</p><p class="p p-last">Our pathway analysis also suggested that the bile acid pathway was implicated in the carfilzomib&#x02010;CVAE. Our pilot study has shed some light on the involvement of mitochondrial dysfunction in carfilzomib&#x02010;CVAE. In our present study, we identified bile acid to be associated with carfilzomib&#x02010;CVAE. Hydrophilic bile acids exhibit cardioprotective effects by promoting the recovery of systolic cardiac function and reducing lactate dehydrogenase release during ischemia&#x02010;reperfusion.<sup><a href="#cts13828-bib-0045" rid="cts13828-bib-0045" class=" bibr popnode">
45
</a></sup> Moreover, their beneficial impact on myocardial reperfusion injury in rats is attributed to the inhibition of the mitochondrial permeability transition pore, a process regulated by the phosphoinositide 3 kinase/PKB pathway.<sup><a href="#cts13828-bib-0046" rid="cts13828-bib-0046" class=" bibr popnode">
46
</a></sup> In individuals with HF, hydrophilic bile acid therapy has demonstrated the ability to enhance both endothelial&#x02010;dependent and non&#x02010;dependent vasodilation, thereby preserving the impaired nitric oxide production in arterial blood flow.<sup><a href="#cts13828-bib-0047" rid="cts13828-bib-0047" class=" bibr popnode">
47
</a></sup> All the available literature suggest that our present finding is consistent with our previous study of carfilzomib&#x02010;CVAE. In light of the prior literature, our study provides a rationale to investigate PI3K/Akt/eNOS pathway further as the underlying mechanism of carfilzomib&#x02010;CVAE.</p></div><div id="cts13828-sec-0018" class="tsec sec"><h2 class="head no_bottom_margin" id="cts13828-sec-0018title">STUDY LIMITATION</h2><p class="p p-first-last">It is important to recognize the limitations of our study. Firstly, even though this is the first metabolomic study in humans to predict carfilzomib&#x02010;CVAE using pretreatment plasma metabolites, the sample size was small. It is likely that we have missed some important metabolites that will provide insight into the risk stratification of MM patients prior to carfilzomib treatment. Secondly, due to the small sample size and the heterogeneity of different CVAE, our study was underpowered to study any specific CVAE such as HF. Full echocardiographic data including diastolic parameters recently implicated in carfilzomib&#x02010;CVAE are not available. Correlation between these parameters with metabolomics should be a focus of future research.<sup><a href="#cts13828-bib-0048" rid="cts13828-bib-0048" class=" bibr popnode">
48
</a></sup><sup>, </sup><sup><a href="#cts13828-bib-0049" rid="cts13828-bib-0049" class=" bibr popnode">
49
</a></sup> Finally, before we can translate this risk stratification tool into the clinical setting, we need to validate the metabolites MRS in an independent study. Clinical decision support could then be developed and implemented into the electronic health records to assist clinicians in identifying high&#x02010;risk MM patients before carfilzomib treatment so that alternative treatment could be considered.</p></div><div id="cts13828-sec-0019" class="tsec sec"><h2 class="head no_bottom_margin" id="cts13828-sec-0019title">CONCLUSION</h2><p class="p p-first-last">In conclusion, we identified baseline bile acid T&#x02010;UDCA to be a potential biomarker for carfilzomib&#x02010;CVAE and we constructed an MRS to stratify MM patients for the risk of carfilzomib&#x02010;CVAE. If validated, this model could be implemented clinically to identify the MM patients at the highest risk for CVAE. In addition, the findings of bile acids provided some intriguing clues for the mechanism of carfilzomib&#x02010;CVAE and potential cardioprotective strategies. Future replication studies are needed to investigate whether these top metabolites, particularly bile acids, are also associated with other drug&#x02010;induced cardiovascular diseases.</p></div><div id="cts13828-sec-0020" class="tsec sec"><h2 class="head no_bottom_margin" id="cts13828-sec-0020title">AUTHOR CONTRIBUTIONS</h2><p class="p p-first-last">S.S. and Y.G. wrote the manuscript; Y.G. and T.J.G. designed the research; S.S., T.N.N., S.M.R, T.J.G. M.T, M.G.F., M.E.A, K.H.S., R.C.B., D.L., R.F.C., Q.L., and Y.G. performed the research; S.S., T.N.N., R.W., and Y.G analyzed the data.</p></div><div id="cts13828-sec-0021" class="tsec sec"><h2 class="head no_bottom_margin" id="cts13828-sec-0021title">FUNDING INFORMATION</h2><p class="p p-first-last">This study was supported by the National Institute of Health grant R01HL151659.</p></div><div id="cts13828-sec-0022" class="tsec sec"><h2 class="head no_bottom_margin" id="cts13828-sec-0022title">CONFLICT OF INTEREST STATEMENT</h2><p class="p p-first-last">M.G.F. received research funding from Medtronic and is on the advisory board with consulting fees for Abbvie, AstraZeneca, Pfizer, Zoll. R.C. B. received research funding from Janssen, Karyopharm, BMS, Abbvie, and is an advisory board member for Janssen, Karyopharm, BMS, Shattuck labs, GSK, Pfizer, Abbvie. R.F.C. is currently employed at AbbVie and is a stock shareholder of AbbVie. R.F.C. was employed at Vanderbilt University Medical Center at the time this research was conducted. S.M.R is anadvisory board member for Janssen, Sanofi, Roche Diagnostics, EUSA pharma. All other authors declared no competing interests for this work.</p></div><div id="sec-a.l.l" class="tsec sec"><a id="supplementary-material-sec"></a><h2 class="head no_bottom_margin" id="sec-a.l.ltitle">Supporting information</h2><!--/article/body/sec/--><div class="sec suppmat" id="cts13828-supitem-0001"><p>
Appendix S1.
</p><div class="sup-box half_rhythm" id="media-a.l.l.b.b"><a href="/pmc/articles/PMC11116757/bin/CTS-17-e13828-s001.docx" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(35K, docx)</sup></div></div></div><div id="notes-a.k.c" class="tsec sec"><h2 class="head no_bottom_margin" id="notes-a.k.ctitle">Notes</h2><p>
<span class="mixed-citation" id="CTS13828-cit-2001">
Shabnaz S, Nguyen TN, Williams R, et al. <span class="ref-title">Metabolomic signatures of carfilzomib&#x02010;related cardiotoxicity in patients with multiple myeloma</span>. <span class="ref-journal">Clin Transl Sci</span>. 2024;<span class="ref-vol">17</span>:e13828. doi: 10.1111/cts.13828
 [<a href="https://pubmed.ncbi.nlm.nih.gov/38783568" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1111%2Fcts.13828" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Transl+Sci&amp;title=Metabolomic+signatures+of+carfilzomib&#x02010;related+cardiotoxicity+in+patients+with+multiple+myeloma&amp;volume=17&amp;publication_year=2024&amp;pages=e13828&amp;doi=10.1111/cts.13828&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span>
</p></div><div id="cts13828-bibl-0001" class="tsec sec"><h2 class="head no_bottom_margin" id="cts13828-bibl-0001title">REFERENCES</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0001">1. <span class="mixed-citation" id="cts13828-cit-0001">
Siegel RL, Giaquinto AN, Jemal A. <span class="ref-title">Cancer statistics, 2024</span>. <span class="ref-journal">CA Cancer J Clin</span>. 2024;<span class="ref-vol">74</span>:12&#x02010;49.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/38230766" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=CA+Cancer+J+Clin&amp;title=Cancer+statistics,+2024&amp;volume=74&amp;publication_year=2024&amp;pages=12-49&amp;pmid=38230766&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0002">2. <span class="mixed-citation" id="cts13828-cit-0002">
Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG. <span class="ref-title">The proteasome and proteasome inhibitors in multiple myeloma</span>. <span class="ref-journal">Cancer Metastasis Rev</span>. 2017;<span class="ref-vol">36</span>:561&#x02010;584.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/29196868" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Metastasis+Rev&amp;title=The+proteasome+and+proteasome+inhibitors+in+multiple+myeloma&amp;volume=36&amp;publication_year=2017&amp;pages=561-584&amp;pmid=29196868&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0003">3. <span class="mixed-citation" id="cts13828-cit-0003">
Stewart AK, Rajkumar SV, Dimopoulos MA, et&#x000a0;al. <span class="ref-title">Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma</span>. <span class="ref-journal">N Engl J Med</span>. 2015;<span class="ref-vol">372</span>:142&#x02010;152.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/25482145" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Carfilzomib,+lenalidomide,+and+dexamethasone+for+relapsed+multiple+myeloma&amp;volume=372&amp;publication_year=2015&amp;pages=142-152&amp;pmid=25482145&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0004">4. <span class="mixed-citation" id="cts13828-cit-0004">
Dimopoulos MA, Moreau P, Palumbo A, et&#x000a0;al. <span class="ref-title">Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open&#x02010;label, multicentre study</span>. <span class="ref-journal">Lancet Oncol</span>. 2016;<span class="ref-vol">17</span>:27&#x02010;38.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/26671818" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet+Oncol&amp;title=Carfilzomib+and+dexamethasone+versus+bortezomib+and+dexamethasone+for+patients+with+relapsed+or+refractory+multiple+myeloma+(ENDEAVOR):+a+randomised,+phase+3,+open&#x02010;label,+multicentre+study&amp;volume=17&amp;publication_year=2016&amp;pages=27-38&amp;pmid=26671818&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0005">5. <span class="mixed-citation" id="cts13828-cit-0005">
Sonneveld P, Asselbergs E, Zweegman S, et&#x000a0;al. <span class="ref-title">Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma</span>. <span class="ref-journal">Blood</span>. 2015;<span class="ref-vol">125</span>:449&#x02010;456.
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4300390/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25398935" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Phase+2+study+of+carfilzomib,+thalidomide,+and+dexamethasone+as+induction/consolidation+therapy+for+newly+diagnosed+multiple+myeloma&amp;volume=125&amp;publication_year=2015&amp;pages=449-456&amp;pmid=25398935&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0006">6. <span class="mixed-citation" id="cts13828-cit-0006">
Teicher BA, Tomaszewski JE. <span class="ref-title">Proteasome inhibitors</span>. <span class="ref-journal">Biochem Pharmacol</span>. 2015;<span class="ref-vol">96</span>:1&#x02010;9.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/25935605" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem+Pharmacol&amp;title=Proteasome+inhibitors&amp;volume=96&amp;publication_year=2015&amp;pages=1-9&amp;pmid=25935605&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0007">7. <span class="mixed-citation" id="cts13828-cit-0007">
Cornell RF, Ky B, Weiss BM, et&#x000a0;al. <span class="ref-title">Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma</span>. <span class="ref-journal">J Clin Oncol</span>. 2019;<span class="ref-vol">37</span>:1946&#x02010;1955.
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC9798911/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31188726" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Prospective+study+of+cardiac+events+during+proteasome+inhibitor+therapy+for+relapsed+multiple+myeloma&amp;volume=37&amp;publication_year=2019&amp;pages=1946-1955&amp;pmid=31188726&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0008">8. <span class="mixed-citation" id="cts13828-cit-0008">
von Haehling S, Schefold JC, Jankowska EA, et&#x000a0;al. <span class="ref-title">Ursodeoxycholic acid in patients with chronic heart failure: a double&#x02010;blind, randomized, placebo&#x02010;controlled, crossover trial</span>. <span class="ref-journal">J Am Coll Cardiol</span>. 2012;<span class="ref-vol">59</span>:585&#x02010;592.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/22300693" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Am+Coll+Cardiol&amp;title=Ursodeoxycholic+acid+in+patients+with+chronic+heart+failure:+a+double&#x02010;blind,+randomized,+placebo&#x02010;controlled,+crossover+trial&amp;volume=59&amp;publication_year=2012&amp;pages=585-592&amp;pmid=22300693&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0009">9. <span class="mixed-citation" id="cts13828-cit-0009">
Kumar S, Paiva B, Anderson KC, et&#x000a0;al. <span class="ref-title">International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma</span>. <span class="ref-journal">Lancet Oncol</span>. 2016;<span class="ref-vol">17</span>:e328&#x02010;e346.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/27511158" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet+Oncol&amp;title=International+myeloma+working+group+consensus+criteria+for+response+and+minimal+residual+disease+assessment+in+multiple+myeloma&amp;volume=17&amp;publication_year=2016&amp;pages=e328-e346&amp;pmid=27511158&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0010">10. <span class="mixed-citation" id="cts13828-cit-0010">
Chamberlain CA, Rubio VY, Garrett TJ. <span class="ref-title">Impact of matrix effects and ionization efficiency in non&#x02010;quantitative untargeted metabolomics</span>. <span class="ref-journal">Metabolomics</span>. 2019;<span class="ref-vol">15</span>:135.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/31584114" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Metabolomics&amp;title=Impact+of+matrix+effects+and+ionization+efficiency+in+non&#x02010;quantitative+untargeted+metabolomics&amp;volume=15&amp;publication_year=2019&amp;pages=135&amp;pmid=31584114&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0011">11. <span class="mixed-citation" id="cts13828-cit-0011">
Pluskal T, Castillo S, Villar&#x02010;Briones A, Oresic M. <span class="ref-title">MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry&#x02010;based molecular profile data</span>. <span class="ref-journal">BMC Bioinform</span>. 2010;<span class="ref-vol">11</span>:395. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2918584/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20650010" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=BMC+Bioinform&amp;title=MZmine+2:+modular+framework+for+processing,+visualizing,+and+analyzing+mass+spectrometry&#x02010;based+molecular+profile+data&amp;volume=11&amp;publication_year=2010&amp;pages=395&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0012">12. <span class="mixed-citation" id="cts13828-cit-0012">
Wang Y, Xiao J, Suzek TO, Zhang J, Wang J, Bryant SH. <span class="ref-title">PubChem: a public information system for analyzing bioactivities of small molecules</span>. <span class="ref-journal">Nucleic Acids Res</span>. 2009;<span class="ref-vol">37</span>:W623&#x02010;W633.
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2703903/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19498078" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nucleic+Acids+Res&amp;title=PubChem:+a+public+information+system+for+analyzing+bioactivities+of+small+molecules&amp;volume=37&amp;publication_year=2009&amp;pages=W623-W633&amp;pmid=19498078&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0013">13. <span class="mixed-citation" id="cts13828-cit-0013">
Kanehisa M, Goto S. <span class="ref-title">KEGG: kyoto encyclopedia of genes and genomes</span>. <span class="ref-journal">Nucleic Acids Res</span>. 2000;<span class="ref-vol">28</span>:27&#x02010;30.
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC102409/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10592173" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nucleic+Acids+Res&amp;title=KEGG:+kyoto+encyclopedia+of+genes+and+genomes&amp;volume=28&amp;publication_year=2000&amp;pages=27-30&amp;pmid=10592173&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0014">14. <span class="mixed-citation" id="cts13828-cit-0014">
Smith CA, O'Maille G, Want EJ, et&#x000a0;al. <span class="ref-title">METLIN: a metabolite mass spectral database</span>. <span class="ref-journal">Ther Drug Monit</span>. 2005;<span class="ref-vol">27</span>:747&#x02010;751.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/16404815" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ther+Drug+Monit&amp;title=METLIN:+a+metabolite+mass+spectral+database&amp;volume=27&amp;publication_year=2005&amp;pages=747-751&amp;pmid=16404815&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0015">15. <span class="mixed-citation" id="cts13828-cit-0015">
Wishart DS, Knox C, Guo AC, et&#x000a0;al. <span class="ref-title">HMDB: a knowledgebase for the human metabolome</span>. <span class="ref-journal">Nucleic Acids Res</span>. 2009;<span class="ref-vol">37</span>:D603&#x02010;D610.
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2686599/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18953024" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nucleic+Acids+Res&amp;title=HMDB:+a+knowledgebase+for+the+human+metabolome&amp;volume=37&amp;publication_year=2009&amp;pages=D603-D610&amp;pmid=18953024&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0016">16. <span class="mixed-citation" id="cts13828-cit-0016">
Patterson RE, Kirpich A, Koelmel J, Kalavalapalli S. <span class="ref-title">Improved experimental data processing for UHPLC&#x02013;HRMS/MS lipidomics applied to nonalcoholic fatty liver disease</span>. <span class="ref-journal">Metabolomics</span>. 2017;<span class="ref-vol">13</span>:1.
 <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Metabolomics&amp;title=Improved+experimental+data+processing+for+UHPLC&#x02013;HRMS/MS+lipidomics+applied+to+nonalcoholic+fatty+liver+disease&amp;volume=13&amp;publication_year=2017&amp;pages=1&amp;pmid=27980501&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0017">17. <span class="mixed-citation" id="cts13828-cit-0017">
Pang Z, Chong J, Zhou G, et&#x000a0;al. <span class="ref-title">MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights</span>. <span class="ref-journal">Nucleic Acids Res</span>. 2021;<span class="ref-vol">49</span>:W388&#x02010;W396.
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8265181/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34019663" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nucleic+Acids+Res&amp;title=MetaboAnalyst+5.0:+narrowing+the+gap+between+raw+spectra+and+functional+insights&amp;volume=49&amp;publication_year=2021&amp;pages=W388-W396&amp;pmid=34019663&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0018">18. <span class="mixed-citation" id="cts13828-cit-0018">
Tibshirani R. <span class="ref-title">The lasso method for variable selection in the cox model</span>. <span class="ref-journal">Stat Med</span>. 1997;<span class="ref-vol">16</span>:385&#x02010;395.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/9044528" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Stat+Med&amp;title=The+lasso+method+for+variable+selection+in+the+cox+model&amp;volume=16&amp;publication_year=1997&amp;pages=385-395&amp;pmid=9044528&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0019">19. <span class="mixed-citation" id="cts13828-cit-0019">
DeLong ER, DeLong DM, Clarke&#x02010;Pearson DL. <span class="ref-title">Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach</span>. <span class="ref-journal">Biometrics</span>. 1988;<span class="ref-vol">44</span>:837&#x02010;845.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/3203132" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biometrics&amp;title=Comparing+the+areas+under+two+or+more+correlated+receiver+operating+characteristic+curves:+a+nonparametric+approach&amp;volume=44&amp;publication_year=1988&amp;pages=837-845&amp;pmid=3203132&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0020">20. <span class="mixed-citation" id="cts13828-cit-0020">
Mortensen LQ, Andresen K, Burcharth J, Pommergaard HC, Rosenberg J. <span class="ref-title">Matching cases and controls using SAS&#x000ae; software</span>. <span class="ref-journal">Front Big Data</span>. 2019;<span class="ref-vol">2</span>:4.
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7931898/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33693327" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front+Big+Data&amp;title=Matching+cases+and+controls+using+SAS&#x000ae;+software&amp;volume=2&amp;publication_year=2019&amp;pages=4&amp;pmid=33693327&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0021">21. <span class="mixed-citation" id="cts13828-cit-0021">
Kr&#x000e4;mer A, Green J, Pollard J, Tugendreich S. <span class="ref-title">Causal analysis approaches in ingenuity pathway analysis</span>. <span class="ref-journal">Bioinformatics</span>. 2014;<span class="ref-vol">30</span>:523&#x02010;530.
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3928520/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24336805" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Bioinformatics&amp;title=Causal+analysis+approaches+in+ingenuity+pathway+analysis&amp;volume=30&amp;publication_year=2014&amp;pages=523-530&amp;pmid=24336805&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0022">22. <span class="mixed-citation" id="cts13828-cit-0022">
Efentakis P, Kremastiotis G, Varela A, et&#x000a0;al. <span class="ref-title">Molecular mechanisms of carfilzomib&#x02010;induced cardiotoxicity in mice and the emerging cardioprotective role of metformin</span>. <span class="ref-journal">Blood</span>. 2019;<span class="ref-vol">133</span>:710&#x02010;723.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/30482794" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Molecular+mechanisms+of+carfilzomib&#x02010;induced+cardiotoxicity+in+mice+and+the+emerging+cardioprotective+role+of+metformin&amp;volume=133&amp;publication_year=2019&amp;pages=710-723&amp;pmid=30482794&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0023">23. <span class="mixed-citation" id="cts13828-cit-0023">
Turdi S, Hu N, Ren J. <span class="ref-title">Tauroursodeoxycholic acid mitigates high fat diet&#x02010;induced cardiomyocyte contractile and intracellular Ca2+ anomalies</span>. <span class="ref-journal">PLoS One</span>. 2013;<span class="ref-vol">8</span>:e63615.
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3647067/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23667647" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+One&amp;title=Tauroursodeoxycholic+acid+mitigates+high+fat+diet&#x02010;induced+cardiomyocyte+contractile+and+intracellular+Ca2++anomalies&amp;volume=8&amp;publication_year=2013&amp;pages=e63615&amp;pmid=23667647&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0024">24. <span class="mixed-citation" id="cts13828-cit-0024">
Timm KN, Tyler DJ. <span class="ref-title">The role of AMPK activation for Cardioprotection in doxorubicin&#x02010;induced cardiotoxicity</span>. <span class="ref-journal">Cardiovasc Drugs Ther</span>. 2020;<span class="ref-vol">34</span>:255&#x02010;269.
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7125062/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32034646" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cardiovasc+Drugs+Ther&amp;title=The+role+of+AMPK+activation+for+Cardioprotection+in+doxorubicin&#x02010;induced+cardiotoxicity&amp;volume=34&amp;publication_year=2020&amp;pages=255-269&amp;pmid=32034646&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0025">25. <span class="mixed-citation" id="cts13828-cit-0025">
Renu K, Abilash VG, Tirupathi Pichiah PB, Arunachalam S. <span class="ref-title">Molecular mechanism of doxorubicin&#x02010;induced cardiomyopathy &#x02013; an update</span>. <span class="ref-journal">Eur J Pharmacol</span>. 2018;<span class="ref-vol">818</span>:241&#x02010;253.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/29074412" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur+J+Pharmacol&amp;title=Molecular+mechanism+of+doxorubicin&#x02010;induced+cardiomyopathy+&#x02013;+an+update&amp;volume=818&amp;publication_year=2018&amp;pages=241-253&amp;pmid=29074412&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0026">26. <span class="mixed-citation" id="cts13828-cit-0026">
Zhang S, Zhou J, Wu W, Zhu Y, Liu X. <span class="ref-title">The role of bile acids in cardiovascular diseases: from mechanisms to clinical implications</span>. <span class="ref-journal">Aging Dis</span>. 2023;<span class="ref-vol">14</span>:261&#x02010;282.
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC10017164/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/37008052" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Aging+Dis&amp;title=The+role+of+bile+acids+in+cardiovascular+diseases:+from+mechanisms+to+clinical+implications&amp;volume=14&amp;publication_year=2023&amp;pages=261-282&amp;pmid=37008052&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0027">27. <span class="mixed-citation" id="cts13828-cit-0027">
Wang Z, Zhao Y. <span class="ref-title">Gut microbiota derived metabolites in cardiovascular health and disease</span>. <span class="ref-journal">Protein Cell</span>. 2018;<span class="ref-vol">9</span>:416&#x02010;431.
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5960473/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29725935" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Protein+Cell&amp;title=Gut+microbiota+derived+metabolites+in+cardiovascular+health+and+disease&amp;volume=9&amp;publication_year=2018&amp;pages=416-431&amp;pmid=29725935&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0028">28. <span class="mixed-citation" id="cts13828-cit-0028">
Orozco&#x02010;Aguilar J, Simon F, Cabello&#x02010;Verrugio C. <span class="ref-title">Redox&#x02010;dependent effects in the physiopathological role of bile acids</span>. <span class="ref-journal">Oxidative Med Cell Longev</span>. 2021;<span class="ref-vol">2021</span>:4847941. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8437588/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34527174" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oxidative+Med+Cell+Longev&amp;title=Redox&#x02010;dependent+effects+in+the+physiopathological+role+of+bile+acids&amp;volume=2021&amp;publication_year=2021&amp;pages=4847941&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0029">29. <span class="mixed-citation" id="cts13828-cit-0029">
Mayerhofer CCK, Ueland T, Broch K, et&#x000a0;al. <span class="ref-title">Increased secondary/primary bile acid ratio in chronic heart failure</span>. <span class="ref-journal">J Card Fail</span>. 2017;<span class="ref-vol">23</span>:666&#x02010;671.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/28688889" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Card+Fail&amp;title=Increased+secondary/primary+bile+acid+ratio+in+chronic+heart+failure&amp;volume=23&amp;publication_year=2017&amp;pages=666-671&amp;pmid=28688889&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0030">30. <span class="mixed-citation" id="cts13828-cit-0030">
Ceylan&#x02010;Isik AF, Sreejayan N, Ren J. <span class="ref-title">Endoplasmic reticulum chaperon tauroursodeoxycholic acid alleviates obesity&#x02010;induced myocardial contractile dysfunction</span>. <span class="ref-journal">J Mol Cell Cardiol</span>. 2011;<span class="ref-vol">50</span>:107&#x02010;116.
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3018539/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21035453" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Mol+Cell+Cardiol&amp;title=Endoplasmic+reticulum+chaperon+tauroursodeoxycholic+acid+alleviates+obesity&#x02010;induced+myocardial+contractile+dysfunction&amp;volume=50&amp;publication_year=2011&amp;pages=107-116&amp;pmid=21035453&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span><link class="retraction-forward" pmcaccid="PMC10915536" /> <a class="red" href="/pmc/articles/PMC10915536/">Retracted</a></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0031">31. <span class="mixed-citation" id="cts13828-cit-0031">
Minamino T, Komuro I, Kitakaze M. <span class="ref-title">Endoplasmic reticulum stress as a therapeutic target in cardiovascular disease</span>. <span class="ref-journal">Circ Res</span>. 2010;<span class="ref-vol">107</span>:1071&#x02010;1082.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/21030724" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Circ+Res&amp;title=Endoplasmic+reticulum+stress+as+a+therapeutic+target+in+cardiovascular+disease&amp;volume=107&amp;publication_year=2010&amp;pages=1071-1082&amp;pmid=21030724&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0032">32. <span class="mixed-citation" id="cts13828-cit-0032">
Fu HY, Minamino T, Tsukamoto O, et&#x000a0;al. <span class="ref-title">Overexpression of endoplasmic reticulum&#x02010;resident chaperone attenuates cardiomyocyte death induced by proteasome inhibition</span>. <span class="ref-journal">Cardiovasc Res</span>. 2008;<span class="ref-vol">79</span>:600&#x02010;610.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/18508854" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cardiovasc+Res&amp;title=Overexpression+of+endoplasmic+reticulum&#x02010;resident+chaperone+attenuates+cardiomyocyte+death+induced+by+proteasome+inhibition&amp;volume=79&amp;publication_year=2008&amp;pages=600-610&amp;pmid=18508854&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0033">33. <span class="mixed-citation" id="cts13828-cit-0033">
Okada K, Minamino T, Tsukamoto Y, et&#x000a0;al. <span class="ref-title">Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis</span>. <span class="ref-journal">Circulation</span>. 2004;<span class="ref-vol">110</span>:705&#x02010;712.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15289376" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Prolonged+endoplasmic+reticulum+stress+in+hypertrophic+and+failing+heart+after+aortic+constriction:+possible+contribution+of+endoplasmic+reticulum+stress+to+cardiac+myocyte+apoptosis&amp;volume=110&amp;publication_year=2004&amp;pages=705-712&amp;pmid=15289376&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0034">34. <span class="mixed-citation" id="cts13828-cit-0034">
Park CS, Cha H, Kwon EJ, Sreenivasaiah PK, Kim DH. <span class="ref-title">The chemical chaperone 4&#x02010;phenylbutyric acid attenuates pressure&#x02010;overload cardiac hypertrophy by alleviating endoplasmic reticulum stress</span>. <span class="ref-journal">Biochem Biophys Res Commun</span>. 2012;<span class="ref-vol">421</span>:578&#x02010;584.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/22525677" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem+Biophys+Res+Commun&amp;title=The+chemical+chaperone+4&#x02010;phenylbutyric+acid+attenuates+pressure&#x02010;overload+cardiac+hypertrophy+by+alleviating+endoplasmic+reticulum+stress&amp;volume=421&amp;publication_year=2012&amp;pages=578-584&amp;pmid=22525677&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0035">35. <span class="mixed-citation" id="cts13828-cit-0035">
Rani S, Sreenivasaiah PK, Kim JO, et&#x000a0;al. <span class="ref-title">Tauroursodeoxycholic acid (TUDCA) attenuates pressure overload&#x02010;induced cardiac remodeling by reducing endoplasmic reticulum stress</span>. <span class="ref-journal">PLoS One</span>. 2017;<span class="ref-vol">12</span>:e0176071.
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5398705/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28426781" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+One&amp;title=Tauroursodeoxycholic+acid+(TUDCA)+attenuates+pressure+overload&#x02010;induced+cardiac+remodeling+by+reducing+endoplasmic+reticulum+stress&amp;volume=12&amp;publication_year=2017&amp;pages=e0176071&amp;pmid=28426781&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0036">36. <span class="mixed-citation" id="cts13828-cit-0036">
Kastritis E, Laina A, Georgiopoulos G, et&#x000a0;al. <span class="ref-title">Carfilzomib&#x02010;induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study</span>. <span class="ref-journal">Leukemia</span>. 2021;<span class="ref-vol">35</span>:1418&#x02010;1427.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/33589757" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Carfilzomib&#x02010;induced+endothelial+dysfunction,+recovery+of+proteasome+activity,+and+prediction+of+cardiovascular+complications:+a+prospective+study&amp;volume=35&amp;publication_year=2021&amp;pages=1418-1427&amp;pmid=33589757&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0037">37. <span class="mixed-citation" id="cts13828-cit-0037">
Chen&#x02010;Scarabelli C, Corsetti G, Pasini E, et&#x000a0;al. <span class="ref-title">Spasmogenic effects of the proteasome inhibitor carfilzomib on coronary resistance, vascular tone and reactivity</span>. <span class="ref-journal">EBioMedicine</span>. 2017;<span class="ref-vol">21</span>:206&#x02010;212.
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5514385/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28587834" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=EBioMedicine&amp;title=Spasmogenic+effects+of+the+proteasome+inhibitor+carfilzomib+on+coronary+resistance,+vascular+tone+and+reactivity&amp;volume=21&amp;publication_year=2017&amp;pages=206-212&amp;pmid=28587834&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0038">38. <span class="mixed-citation" id="cts13828-cit-0038">
Hong J, Kim K, Kim JH, Park Y. <span class="ref-title">The role of endoplasmic reticulum stress in cardiovascular disease and exercise</span>. <span class="ref-journal">Int J Vasc Med</span>. 2017;<span class="ref-vol">2017</span>:2049217.
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5569752/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28875043" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Vasc+Med&amp;title=The+role+of+endoplasmic+reticulum+stress+in+cardiovascular+disease+and+exercise&amp;volume=2017&amp;publication_year=2017&amp;pages=2049217&amp;pmid=28875043&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0039">39. <span class="mixed-citation" id="cts13828-cit-0039">
Lenihan DJ. <span class="ref-title">The horizon in cardio&#x02010;oncology: &#x0201c;you are only as good as your endothelium&#x0201d;</span>. <span class="ref-journal">J Am Coll Cardiol</span>. 2017;<span class="ref-vol">70</span>:163&#x02010;164.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/28683963" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Am+Coll+Cardiol&amp;title=The+horizon+in+cardio&#x02010;oncology:+&#x0201c;you+are+only+as+good+as+your+endothelium&#x0201d;&amp;volume=70&amp;publication_year=2017&amp;pages=163-164&amp;pmid=28683963&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0040">40. <span class="mixed-citation" id="cts13828-cit-0040">
Philipp S, Cui L, Ludolph B, et&#x000a0;al. <span class="ref-title">Desferoxamine and ethyl&#x02010;3,4&#x02010;dihydroxybenzoate protect myocardium by activating NOS and generating mitochondrial ROS</span>. <span class="ref-journal">Am J Physiol Heart Circ Physiol</span>. 2006;<span class="ref-vol">290</span>:H450&#x02010;H457.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/16155105" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Physiol+Heart+Circ+Physiol&amp;title=Desferoxamine+and+ethyl&#x02010;3,4&#x02010;dihydroxybenzoate+protect+myocardium+by+activating+NOS+and+generating+mitochondrial+ROS&amp;volume=290&amp;publication_year=2006&amp;pages=H450-H457&amp;pmid=16155105&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0041">41. <span class="mixed-citation" id="cts13828-cit-0041">
Aswar U, Mahajan U, Kandhare A, Aswar M. <span class="ref-title">Ferulic acid ameliorates doxorubicin&#x02010;induced cardiac toxicity in rats</span>. <span class="ref-journal">Naunyn Schmiedeberg's Arch Pharmacol</span>. 2019;<span class="ref-vol">392</span>:659&#x02010;668.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/30734092" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Naunyn+Schmiedeberg's+Arch+Pharmacol&amp;title=Ferulic+acid+ameliorates+doxorubicin&#x02010;induced+cardiac+toxicity+in+rats&amp;volume=392&amp;publication_year=2019&amp;pages=659-668&amp;pmid=30734092&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0042">42. <span class="mixed-citation" id="cts13828-cit-0042">
Song Y, Zhang C, Wang C, et&#x000a0;al. <span class="ref-title">Ferulic acid against cyclophosphamide&#x02010;induced heart toxicity in mice by inhibiting NF&#x02010;&#x003ba;B pathway</span>. <span class="ref-journal">Evid Based Complement Alternat Med</span>. 2016;<span class="ref-vol">2016</span>:1261270.
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4736310/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26881001" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Evid+Based+Complement+Alternat+Med&amp;title=Ferulic+acid+against+cyclophosphamide&#x02010;induced+heart+toxicity+in+mice+by+inhibiting+NF&#x02010;&#x003ba;B+pathway&amp;volume=2016&amp;publication_year=2016&amp;pages=1261270&amp;pmid=26881001&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0043">43. <span class="mixed-citation" id="cts13828-cit-0043">
He Y, Sun MM, Zhang GG, et&#x000a0;al. <span class="ref-title">Targeting PI3K/Akt signal transduction for cancer therapy</span>. <span class="ref-journal">Signal Transduct Target Ther</span>. 2021;<span class="ref-vol">6</span>:425.
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8677728/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34916492" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Signal+Transduct+Target+Ther&amp;title=Targeting+PI3K/Akt+signal+transduction+for+cancer+therapy&amp;volume=6&amp;publication_year=2021&amp;pages=425&amp;pmid=34916492&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0044">44. <span class="mixed-citation" id="cts13828-cit-0044">
Zhang R, Ma WQ, Fu MJ, et&#x000a0;al. <span class="ref-title">Overview of bile acid signaling in the cardiovascular system</span>. <span class="ref-journal">World J Clin Cases</span>. 2021;<span class="ref-vol">9</span>:308&#x02010;320.
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7812903/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33521099" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=World+J+Clin+Cases&amp;title=Overview+of+bile+acid+signaling+in+the+cardiovascular+system&amp;volume=9&amp;publication_year=2021&amp;pages=308-320&amp;pmid=33521099&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0045">45. <span class="mixed-citation" id="cts13828-cit-0045">
Lee WY, Han SH, Cho TS, Yoo YH, Lee SM. <span class="ref-title">Effect of ursodeoxycholic acid on ischemia/reperfusion injury in isolated rat heart</span>. <span class="ref-journal">Arch Pharm Res</span>. 1999;<span class="ref-vol">22</span>:479&#x02010;484.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/10549575" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Arch+Pharm+Res&amp;title=Effect+of+ursodeoxycholic+acid+on+ischemia/reperfusion+injury+in+isolated+rat+heart&amp;volume=22&amp;publication_year=1999&amp;pages=479-484&amp;pmid=10549575&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0046">46. <span class="mixed-citation" id="cts13828-cit-0046">
Rajesh KG, Suzuki R, Maeda H, Yamamoto M, Yutong X, Sasaguri S. <span class="ref-title">Hydrophilic bile salt ursodeoxycholic acid protects myocardium against reperfusion injury in a PI3K/Akt dependent pathway</span>. <span class="ref-journal">J Mol Cell Cardiol</span>. 2005;<span class="ref-vol">39</span>:766&#x02010;776.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/16171810" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Mol+Cell+Cardiol&amp;title=Hydrophilic+bile+salt+ursodeoxycholic+acid+protects+myocardium+against+reperfusion+injury+in+a+PI3K/Akt+dependent+pathway&amp;volume=39&amp;publication_year=2005&amp;pages=766-776&amp;pmid=16171810&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0047">47. <span class="mixed-citation" id="cts13828-cit-0047">
Sinisalo J, Vanhanen H, Pajunen P, Vapaatalo H, Nieminen MS. <span class="ref-title">Ursodeoxycholic acid and endothelial&#x02010;dependent, nitric oxide&#x02010;independent vasodilatation of forearm resistance arteries in patients with coronary heart disease</span>. <span class="ref-journal">Br J Clin Pharmacol</span>. 1999;<span class="ref-vol">47</span>:661&#x02010;665.
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2014254/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10383544" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Br+J+Clin+Pharmacol&amp;title=Ursodeoxycholic+acid+and+endothelial&#x02010;dependent,+nitric+oxide&#x02010;independent+vasodilatation+of+forearm+resistance+arteries+in+patients+with+coronary+heart+disease&amp;volume=47&amp;publication_year=1999&amp;pages=661-665&amp;pmid=10383544&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0048">48. <span class="mixed-citation" id="cts13828-cit-0048">
Astarita A, Mingrone G, Airale L, et&#x000a0;al. <span class="ref-title">Cardiovascular risk assessment in multiple myeloma patients undergoing carfilzomib therapy: a new risk prediction model for cardiovascular adverse events</span>. <span class="ref-journal">Eur Heart J Cardiovasc Imaging</span>. 2021;<span class="ref-vol">22</span>:jeaa356&#x02010;424. <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur+Heart+J+Cardiovasc+Imaging&amp;title=Cardiovascular+risk+assessment+in+multiple+myeloma+patients+undergoing+carfilzomib+therapy:+a+new+risk+prediction+model+for+cardiovascular+adverse+events&amp;volume=22&amp;publication_year=2021&amp;pages=jeaa356-424&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cts13828-bib-0049">49. <span class="mixed-citation" id="cts13828-cit-0049">
Makris N, Georgiopoulos G, Laina A, et&#x000a0;al. <span class="ref-title">Cardiac mechanics in response to proteasome inhibition: a prospective study</span>. <span class="ref-journal">Eur Heart J Cardiovasc Imaging</span>. 2022;<span class="ref-vol">24</span>:643&#x02010;652. [<a href="https://pubmed.ncbi.nlm.nih.gov/35980754" ref="reftype=pubmed&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur+Heart+J+Cardiovasc+Imaging&amp;title=Cardiac+mechanics+in+response+to+proteasome+inhibition:+a+prospective+study&amp;volume=24&amp;publication_year=2022&amp;pages=643-652&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11116757&amp;issue-id=461639&amp;journal-id=2996&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr /><div class="half_rhythm">Articles from <span class="acknowledgment-journal-title">Clinical and Translational Science</span> are provided here courtesy of <strong>Wiley</strong></div><hr /></div><div id="body-link-poppers"><span></span></div></div>
            
        </section>
    </article>
    <aside class="usa-width-one-fourth usa-layout-docs-sidenav pmc-sidebar">
         
  

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC11116757/pdf/CTS-17-e13828.pdf" class="int-view">PDF (3.8M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/11116757/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/11116757/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="11116757" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC11116757%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="MUwiGn2d5D94sC2YjPCziUF6f3jWuEvBrd0tns3fJHEmEgDqYZthGdeWgiDwBwuJ">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-aside "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-aside ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-aside "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-aside ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC11116757%2F&amp;text=Metabolomic%20signatures%20of%20carfilzomib%02010related%20cardiotoxicity%20in%20patients%20with%20multiple%20myeloma" alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC11116757%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11116757/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC11116757/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/38783568/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-aside" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC11116757/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/38783568/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-aside"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC11116757/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/11116757/" class="usa-accordion-content" id="links-accordion-aside" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>

    </aside>
</main>

    <div class="overlay" role="dialog" aria-label="Citation Dialog">
  <div class="dialog citation-dialog">
    <button class="close-overlay" tabindex="1">[x]</button>
    <div class="title">Cite</div>
    <div class="citation-text-block">
  <div class="citation-text"></div>
  <div class="citation-actions">
    <button
      class="copy-button dialog-focus"
      data-ga-category="save_share"
      data-ga-action="cite"
      data-ga-label="copy"
      tabindex="2">
      Copy
    </button>

      <a href="#"
              class="export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
          <span class="title">Download .nbib</span>
          <span class="title-mobile">.nbib</span>
      </a>


    

<div class="citation-style-selector-wrapper">
  <label class="selector-label">Format:</label>
  <select aria-label="Format" class="citation-style-selector" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
  </div>
</div>
  </div>
</div>

     <!-- ========== BEGIN FOOTER ========== -->
 <footer>
      <section class="icon-section">
        <div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
        <div class="grid-container container">
          <div class="icon-section_container">
            <a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11 {
                      fill: #737373;
                    }
                  </style>
                </defs>
                <title>Twitter</title>
                <path class="cls-11"
                  d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>Facebook</title>
                <path class="cls-11"
                  d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_linkedin"
              href="https://www.linkedin.com/company/ncbinlm"
              aria-label="LinkedIn"><svg data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>LinkedIn</title>
                <path class="cls-11"
                  d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11,
                    .cls-12 {
                      fill: #737373;
                    }

                    .cls-11 {
                      fill-rule: evenodd;
                    }
                  </style>
                </defs>
                <title>GitHub</title>
                <path class="cls-11"
                  d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
                </path>
                <path class="cls-12"
                  d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
                </path>
                <path class="cls-12"
                  d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
                </path>
                <path class="cls-12"
                  d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
                <path class="cls-12"
                  d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
                </path>
                <path class="cls-12"
                  d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
                </path>
                <path class="cls-12"
                  d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
                </path>
                <path class="cls-12"
                  d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
              </svg></a>
            <a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
              <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40"><defs><style>.cls-1{fill:#737373;}</style></defs><path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"/></svg>
            </a>
          </div>
        </div>
      </section>

      <section class="container-fluid bg-primary">
        <div class="container pt-5">
          <div class="row mt-3">
            <div class="col-lg-3 col-12">
              <p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
              <ul class="list-inline social_media">
                <li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st20 {
                          fill: #FFFFFF;
                        }

                        .st30 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Twitter</title>
                      <g>
                        <g>
                          <g>
                            <path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7
                                                c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116
                                                c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3
                                                c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6
                                                C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
                          </g>
                        </g>
                        <circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
                      </g>
                    </svg></a></li>
                <li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine"
                    aria-label="Facebook" rel="noopener noreferrer" target="_blank">
                    <svg version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px"
                      y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st10 {
                          fill: #FFFFFF;
                        }

                        .st110 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Facebook</title>
                      <g>
                        <g>
                          <path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9
                                                      v67.5H135v-67.5h21.7L159,99.1z"></path>
                        </g>
                      </g>
                      <circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
                    </svg>
                  </a></li>
                <li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <title>SM-Youtube</title>
                      <style type="text/css">
                        .st4 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }

                        .st5 {
                          fill: #FFFFFF;
                        }
                      </style>
                      <circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
                      <g transform="translate(0,-952.36218)">
                        <path class="st5"
                          d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7
                                            v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
                      </g>
                    </svg></a></li>
              </ul>
            </div>
            <div class="col-lg-3 col-12">
              <p class="address_footer text-white">National Library of Medicine<br>
                <a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323"
                  class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br>
                  Bethesda, MD 20894</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br>
                <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office"
                  class="text-white">FOIA</a><br>
                <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br>
                <a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br>
                <a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
            </div>
          </div>
          <div class="row">
            <div class="col-lg-12 centered-lg">
              <nav class="bottom-links">
                <ul class="mt-3">
                  <li>
                    <a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
                  </li>
                  <li>
                    <a class="text-white"
                  href="https://www.nih.gov/">NIH</a>
                  </li>
                  <li>
                    <a class="text-white" href="https://www.hhs.gov/">HHS</a>
                  </li>
                  <li>
                    <a
                  class="text-white" href="https://www.usa.gov/">USA.gov</a>
                  </li>
                </ul>
              </nav>
            </div>
          </div>
        </div>
      </section>
    </footer>
 <!-- ========== END FOOTER ========== -->
  <!-- javascript to inject NWDS meta tags. Note: value of nwds_version is updated by "npm version" command -->
 
  <script type="text/javascript">
    var nwds_version = "1.1.9-2";

    var meta_nwds_ver = document.createElement('meta');
    meta_nwds_ver.name = 'ncbi_nwds_ver';
    meta_nwds_ver.content = nwds_version;
    document.getElementsByTagName('head')[0].appendChild(meta_nwds_ver);

    var meta_nwds = document.createElement('meta');
    meta_nwds.name = 'ncbi_nwds';
    meta_nwds.content = 'yes';
    document.getElementsByTagName('head')[0].appendChild(meta_nwds);

	var alertsUrl = "/core/alerts/alerts.js";
	if (typeof ncbiBaseUrl !== 'undefined') {
		alertsUrl = ncbiBaseUrl + alertsUrl;
	}
  </script>



  
    <!-- JavaScript -->
    <script src="/pmc/static/CACHE/js/output.0f72d6a64937.js"></script>
  
  
    <script src="https://code.jquery.com/jquery-3.5.0.min.js"
          integrity="sha256-xNzN2a4ltkB44Mc/Jz3pT4iU1cmeR0FkXs4pru/JxaQ="
          crossorigin="anonymous">
    </script>
    <script>
        var fallbackJquery = "/pmc/static/base/js/jquery-3.5.0.min.js";
        window.jQuery || document.write("<script src=" + fallbackJquery + ">\x3C/script>")
    </script>
  

  <script src="/pmc/static/CACHE/js/output.a212a9fcf845.js"></script>
<script src="/pmc/static/CACHE/js/output.7999321d1aac.js"></script>
<script src="/pmc/static/CACHE/js/output.7ca436b2ea51.js"></script>
<script src="/pmc/static/CACHE/js/output.f8422046fbe0.js"></script>
<script src="/pmc/static/CACHE/js/output.ff40c7d85ff8.js"></script>
<script src="/pmc/static/CACHE/js/output.a6a84a0ad361.js"></script>

<script type="text/javascript" src="/pmc/static/bundles/base/base.038d36e4e31104b40a19.js" ></script>

    <script type="text/javascript">
        if(typeof jQuery !=='undefined') {
            jQuery.migrateMute = true;
        }
    </script>
    <script type="text/javascript" src="https://code.jquery.com/jquery-migrate-1.4.1.js"></script>
    <script type="text/javascript" src="/core/jig/1.15.2/js/jig.nojquery.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/crb.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/jactions.min.js?_=3.18">//</script><script type="text/javascript">window.name="mainwindow";</script>

    <script type="text/javascript">var exports = {};</script>
    <script src="/pmc/static/CACHE/js/output.340a3b9cce7f.js"></script>
<script src="/pmc/static/CACHE/js/output.228f96f3298e.js"></script>
    <script type="text/javascript" src="/pmc/static/bundles/article/article.b7dd20e527283dd68f45.js" ></script>
    <script type="text/javascript">
        window.ncbi.pmc.articlePage.init({ pageURL: '/pmc/articles/PMC11116757/', citeCookieName: 'pmc-cf'});
    </script>


  
  
  <script  type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


  
      
  

</body>
</html>
